brinzolamide profile

Brinzolamide is a carbonic anhydrase inhibitor used to treat open-angle glaucoma and ocular hypertension. It works by decreasing the production of aqueous humor, the fluid that fills the eye, which helps to lower intraocular pressure. Brinzolamide is available as an ophthalmic solution. Its synthesis involves a multi-step process starting from commercially available starting materials. Brinzolamide is important because it offers an effective treatment option for glaucoma, a leading cause of blindness. It is studied extensively to investigate its efficacy and safety, as well as to explore its potential in other ophthalmological conditions.'

brinzolamide: an antiglaucoma agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	68844
CHEMBL ID	220491
CHEBI ID	3176
SCHEMBL ID	24636
MeSH ID	M0289415

Synonym
AC-5277
BIDD:GT0039
MLS002153787
smr001233169
BRD-K74913225-001-03-3
nsc-760050
CHEMBL220491
al-4862
brinzolamide [usan]
(r)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2h-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide
al 4862
azopt
(r)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2h-thieno(3,2-e)-1,2-thiazine-6-sulfonamide
2h-thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (r)-
BSPBIO_000489
BPBIO1_000539
PRESTWICK3_000365
PRESTWICK2_000365
AB00513824
C07760
138890-62-7
brinzolamide
3ZNC
DB01194
brinzolamide (brz)
CHEBI:3176 ,
(4r)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
(4r)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2h,3h,4h-1$l^{6},7,2-thieno[3,2-e][1,2]thiazine-6-sulfonamide
bdbm10885
azopt (tn)
(+)-4-ethylamino-3,4-dihydro-2-(methoxy)propyl-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide
BZ1 ,
brinzolamide (jan/usp/inn)
D00652
PRESTWICK1_000365
PRESTWICK0_000365
SPBIO_002410
(4r)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
AKOS005145708
HMS1569I11
(r)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide
HMS2096I11
dtxsid6045531 ,
tox21_110722
dtxcid4025531
HMS2234K06
S3178
brinzolamide [usan:usp:inn:ban]
nsc 760050
unii-9451z89515
9451z89515 ,
brinzolamide component of simbrinza
brinzolamide [inn]
simbrinza component brinzolamide
brinzolamide component of azarga
brinzolamide [usp monograph]
brinzolamide [who-dd]
brinzolamide [vandf]
brinzolamide [ema epar]
brinzolamide [orange book]
azarga component brinzolamide
brinzolamide [mart.]
brinzolamide [jan]
brinzolamide [usp-rs]
brinzolamide [mi]
brinzolamide [usp impurity]
gtpl6797
(4r)-4-ethylamino-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[4,5-e]thiazine-6-sulfonamide
CCG-220365
CCG-222516
HY-B0588
(r)-3,4-dihydro-4-ethylamino-2-(3-methoxypropyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide
HCRKCZRJWPKOAR-JTQLQIEISA-N
SCHEMBL24636
tox21_110722_1
NCGC00179542-03
(4r)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide
Q-200751
(r)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
B4258
AB00513824_06
(4r)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2h,3h,4h-1$l^{6},7,2-thieno[3,2-e][1$l^{6},2]thiazine-6-sulfonamide
SR-01000838832-2
sr-01000838832
brinzolamide, united states pharmacopeia (usp) reference standard
(4r)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide-1,1-dioxide
brinzolamide, >=98% (hplc)
2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (4r)-
HMS3713I11
SW197152-3
138890-50-3
BCP22330
Q411517
(5r)-5-ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2,9-dithia-3-azabicyclo[4.3.0]nona-1(6)7-diene-8-sulfonamide
AS-35084
NCGC00179542-10
HMS3885I11
AMY372
NCGC00179542-09
brinzolamide- bio-x
BB164262
s01ec04
brinzolamide (usp-rs)
brinzolamide (mart.)
(r)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2h-thieno(3,2,e)-1,2-thiazine-6-sulfonamide 1,1-dioxide
(4r)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2h-thieno(3,2-e)(1,2)thiazine-6-sulfonamide 1,1-dioxide
brinzolamida
brinzolamide (usp monograph)
brinzolamide (usp impurity)
brinzolamidum
EN300-7404820
(4r)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-2h,3h,4h-1lambda6-thieno[3,2-e][1,2]thiazine-6-sulfonamide

Excerpt	Reference	Relevance
"Brinzolamide is an effective carbonic anhydrase inhibitor widely used in glaucoma therapy but limits its application due to inadequate aqueous solubility and permeability. "	( Exploring Penetration Ability of Carbonic Anhydrase Inhibitor-Loaded Ultradeformable Bilosome for Effective Ocular Application. Bhavana, V; Mehra, NK; Nair, VS; Rajana, N; Singh, SB; Srivastava, V; Yadav, R, 2023)	2.35
"Brinzolamide (BNZ) is a carbonic anhydrase inhibitor commonly used for the treatment of glaucoma. "	( Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study. Dangi, JS; Dubey, V; Kesavan, K; Mohan, P, 2020)	3.44
"Brinzolamide (BLZ) is a drug used to treat glaucoma; however, its use is restricted due to some unwanted adverse events. "	( Ophthalmic delivery of brinzolamide by liquid crystalline nanoparticles: in vitro and in vivo evaluation. Li, J; Wang, B; Wang, Z; Wu, L; Wu, W; Xin, H; Xu, Q, 2013)	2.14
"Brinzolamide (BRZ) is a kind of carbonic anhydrase inhibitors for glaucoma treatment."	( Development of inclusion complex of brinzolamide with hydroxypropyl-β-cyclodextrin. Chen, T; He, G; He, Z; Lei, Y; Li, H; Ren, K; Song, X; Xia, S; Xie, Y; Zhang, Y; Zheng, Y, 2013)	1.39
"Brinzolamide is a highly specific carbonic anhydrase (CA) inhibitor which lowers intraocular pressure (IOP) by reducing the rate of aqueous humour formation. "	( Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Cvetkovic, RS; Perry, CM, 2003)	3.2
"Brinzolamide is a new topical carbonic anhydrase inhibitor for intraocular pressure (IOP) control. "	( Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. Chen, YF; Huang, JY; Hung, PT; Shieh, JW; Wang, TH, 2004)	2.03
"Brinzolamide is a new topically active CAI that is safe a"	( Preclinical overview of brinzolamide. DeSantis, L, 2000)	1.34
"Brinzolamide is a novel carbonic anhydrase inhibitor that elicits an ocular hypotensive effect when instilled topically. "	( Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide Dose-Response Study Group. Silver, LH, 2000)	1.99

Excerpt	Reference	Relevance
"Brinzolamide/brimonidine has increased by 50.0% from 2016 to 2017."	( Prescribing Trends of Topical Glaucoma Medications in Australia From 2001 to 2017. Chen, O; Jamieson, MPH; Ling, D; Perera, N; Pinnuck, BC; Williams, M, 2020)	1.28
"Brinzolamide has been shown by the laser Doppler flowmetry technique to improve blood flow to the optic nerve head in pigmented rabbits after topical administration, without producing an increase of blood pCO2, indicating a potential for a local vasodilatory effect involving the optic nerve head circulation."	( Preclinical overview of brinzolamide. DeSantis, L, 2000)	1.34

Excerpt	Reference	Relevance
"Brinzolamide may cause a short-term increase in the human CCT, particularly on the first day."	( Short-term effect of topical brinzolamide on human central corneal thickness. Ergin, A; Gullu, R; Ogurel, T; Ornek, K, )	1.87

Excerpt	Reference	Relevance
"Treatment with brinzolamide/travoprost caused statistically significant sustained reduction in intraocular pressure with the reduction of 17.39% (p < 0.001) after 4 weeks and 20.08% (p < 0.001) after 12 weeks."	( [Adjunctive therapy with brinzolamide in patients on travoprost treatment]. Andreić, V; Babić, N; Barisić, S; Canadanović, V; Miljković, A, )	0.77
"Treatment with brinzolamide 1.0% was safe, comfortable, and well tolerated."	( Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Silver, LH, 1998)	0.92

Excerpt	Reference	Relevance
" One hundred forty-four patients were discontinued from the study after randomization with the most common reasons being the occurrence of an adverse event (46), inadequate intraocular pressure control (23), patient decision unrelated to study medication (11), lost to follow-up (16), and noncompliance (9)."	( The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. March, WF; Ochsner, KI, 2000)	0.58
" Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort."	( The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. March, WF; Ochsner, KI, 2000)	1.49
" The most frequent side effect was ocular pain in the case of 2% dorzolamide and blurred vision in 1% brinzolamide."	( Comparisons of intraocular-pressure- lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide. Chu, YK; Hong, YJ; Lee, JH; Lee, SC; Seong, GJ, )	0.56
" The study medications were generally well tolerated and no serious adverse reactions occurred during the 6-week study period."	( Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. Chen, YF; Huang, JY; Hung, PT; Shieh, JW; Wang, TH, 2004)	0.59
" Adverse events were recorded at each visit."	( Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of efficacy and safety. Castillo, A; Fernandez-Vidal, A; Garcia-Feijoo, J; Garcia-Sanchez, J; Martinez-de-la-Casa, JM; Mendez-Hernandez, C, 2004)	0.58
" Common adverse events were mild and included ocular hyperaemia, dysgeusia and eye irritation."	( Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. Franks, W, 2006)	0.6
" The IOP and the side effect before and after the administration of the eyedrops were observed."	( [Clinical investigation: the intraocular pressure-lowering efficacy and safety of brinzolamide combined with betaxolol]. Fang, M; Ge, J; Huang, S; Minbin, Y, 2005)	0.55
"Brinzolamide combined with Betaxolol has significant IOP lowering effect and few side effect for the Chinese people."	( [Clinical investigation: the intraocular pressure-lowering efficacy and safety of brinzolamide combined with betaxolol]. Fang, M; Ge, J; Huang, S; Minbin, Y, 2005)	2
" There was no significant difference for any adverse event between groups (p>0."	( The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Berta, A; Chiselita, D; Cvenkel, B; Holló, G; Izgi, B; Liehneova, I; Petkova, N; Stewart, WC; Szaflik, J; Turacli, E, )	0.38
" As systemic adverse events, there was one instance of malar flushing after brinzolamide addition and episodes of chest discomfort after timolol addition in 1 patient."	( Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. Ito, K; Matsunaga, K; Miura, K; Okawa, C; Sugimoto, K; Uji, Y, )	0.61
" A total of 143 patients experienced at least 1 treatment-related adverse event (AE; BBFC group, n=58, 26."	( Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%. Goode, SM; McMenemy, MG; Nguyen, QH; Realini, T; Whitson, JT, 2013)	0.61
"To investigate whether a self-reported history of allergy to sulfa-based drugs is a predictor for subsequent adverse reactions to topical carbonic anhydrase inhibitors (CAIs)."	( Evaluation of adverse events in self-reported sulfa-allergic patients using topical carbonic anhydrase inhibitors. Guedes, GB; Karan, A; Mayer, HR; Shields, MB, 2013)	0.39
" The outcome measure was the development of an adverse reaction (either ocular, systemic, or both) within at least 30 days after receipt of 1 of 4 classes of topical glaucoma medications: CAIs (dorzolamide and brinzolamide), prostaglandin analogues, beta-adrenergic blockers, and alpha2-adrenergic agonists."	( Evaluation of adverse events in self-reported sulfa-allergic patients using topical carbonic anhydrase inhibitors. Guedes, GB; Karan, A; Mayer, HR; Shields, MB, 2013)	0.58
"Patients with a self-reported history of sulfa allergy had significantly more ocular adverse reactions after the initiation of any of the topical antiglaucoma medications when compared to those patients with no reported allergies."	( Evaluation of adverse events in self-reported sulfa-allergic patients using topical carbonic anhydrase inhibitors. Guedes, GB; Karan, A; Mayer, HR; Shields, MB, 2013)	0.39
"It may be safe to use a topical CAI in patients who report a history of a sulfa allergy."	( Evaluation of adverse events in self-reported sulfa-allergic patients using topical carbonic anhydrase inhibitors. Guedes, GB; Karan, A; Mayer, HR; Shields, MB, 2013)	0.39
" Safety was assessed with adverse event rates, ocular discomfort score, blur scale, blood pressure and heart rates, best-corrected visual acuity (BCVA) and slit lamp examinations."	( Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients. Adachi, M; Aihara, M; Fukuchi, T; Matsuo, H; Sasaki, N; Togano, T, 2017)	0.69
" Thus, BTFC can be considered as a safe and effective agent for glaucoma treatment."	( Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients. Adachi, M; Aihara, M; Fukuchi, T; Matsuo, H; Sasaki, N; Togano, T, 2017)	0.69
" The intraocular pressure (IOP), mean deviation value, and adverse drug reactions were evaluated."	( The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study. Jin, SW; Lee, SM, 2018)	0.73
" There were no serious adverse drug reactions."	( The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study. Jin, SW; Lee, SM, 2018)	0.73
"BBFC provides a significant IOP reduction and is a safe antiglaucoma medication for NTG patients."	( The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study. Jin, SW; Lee, SM, 2018)	0.73
"BBFC had satisfactory IOP-lowering effects without serious adverse reactions in patients who switched medications."	( Intraocular pressure-lowering effects and safety of brimonidine/brinzolamide fixed combination after switching from other medications. Inoue, K; Ishida, K; Kunimatsu-Sanuki, S; Tomita, G, 2022)	0.96

Excerpt	Reference	Relevance
" Pharmacokinetic parameters (C(max), T(max), and AUC(0-24)) were estimated by noncompartmental analysis."	( Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow. Jadhav, G; Kadam, RS; Kompella, UB; Ogidigben, M, 2011)	0.63
" The pharmacodynamic studies were conducted for CPNCs on glaucoma induced rabbit eye model and compared with marketed product."	( Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study. Dangi, JS; Dubey, V; Kesavan, K; Mohan, P, 2020)	2
" In pharmacodynamic study, greater intraocular pressure lowering effect was achieved by CPNCs as compared to marketed drug product."	( Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study. Dangi, JS; Dubey, V; Kesavan, K; Mohan, P, 2020)	2

Excerpt	Reference	Relevance
"To evaluate the intraocular pressure (IOP) lowering efficacy and safety of Brinzolamide combined with Betaxolol for the Chinese glaucomatous patients."	( [Clinical investigation: the intraocular pressure-lowering efficacy and safety of brinzolamide combined with betaxolol]. Fang, M; Ge, J; Huang, S; Minbin, Y, 2005)	0.78
"Brinzolamide combined with Betaxolol has significant IOP lowering effect and few side effect for the Chinese people."	( [Clinical investigation: the intraocular pressure-lowering efficacy and safety of brinzolamide combined with betaxolol]. Fang, M; Ge, J; Huang, S; Minbin, Y, 2005)	2
"The multiple drug interactions in which CAIs are involved should be carefully considered when such drugs are used in combination with the drug classes mentioned above, as the risks of developing toxicity and serious side effects if the dosages are not adjusted are high."	( Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Supuran, CT, 2016)	0.43
"To examine the relevance of concentration of benzalkonium chloride (BAK) on the cornea, we investigated the effects of latanoprost containing BAK alone and in combination with other antiglaucoma drug classes on corneal epithelium in vitro in a cultured rabbit corneal cell line (SIRC) and in vivo, using a corneal resistance device (CRD)."	( In vitro and in vivo corneal effects of latanoprost combined with brimonidine, timolol, dorzolamide, or brinzolamide. Fukuda, M; Sasaki, H; Shibata, N; Shibata, S; Shibata, T; Sugiyama, K; Takeda, N, 2016)	0.65

Excerpt	Reference	Relevance
" Furthermore, the bioavailability of these derivatives in rabbits is comparable to that of acetazolamide, being in the range of 85-90%, showing them as promising candidates for systemically acting CA inhibitors."	( Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails. Scozzafava, A; Supuran, CT, 2002)	0.31
" Thus this formulation is safe for ophthalmic use and significantly increases brinzolamide bioavailability in aqueous humor."	( Design and evaluation of a brinzolamide drug-resin in situ thermosensitive gelling system for sustained ophthalmic drug delivery. Cai, CN; Li, J; Liu, H; Liu, LL; Liu, W; Xin, HX, 2014)	0.93
" However, the conventional formulation of TM and BRZ exhibits sub optimal therapeutic effects attributable to the poor ocular bioavailability of these drugs."	( Fabrication and Characterization of Timolol Maleate and Brinzolamide Loaded Nanostructured Lipid Carrier System for Ocular Drug Delivery. Ali, J; Baboota, S; Khan, S; Shrivastava, N, 2018)	0.73
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"The result concluded that CPNCs are a feasible choice to conventional eye drops because of its ability to improve the bioavailability via its longer precorneal retention time and its ability to sustained release of the drug."	( Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study. Dangi, JS; Dubey, V; Kesavan, K; Mohan, P, 2020)	2
"In recent years, the hydrophobic active substances have led researchers to develop new formulations to enhance bioavailability and dissolution rate; brinzolamide, a lipophilic drug belongs to carbonic anhydrase inhibitors, which cause reduction of intraocular pressure in patients suffering from glaucoma."	( Ocular microemulsion of brinzolamide: Formulation, physicochemical characterization, and in vitro irritation studies based on EpiOcular™ eye irritation assay. Aydın, A; Çağlar, EŞ; Charehsaz, M; Siafaka, PI; Sipahi, H; Üstündağ Okur, N, 2021)	1.13

Excerpt	Relevance	Reference
" The degree of tolerability in the eye is considered an important determinant of a patient's willingness to comply with the dosing regimen for a long-term glaucoma medication."	( Preclinical overview of brinzolamide. DeSantis, L, 2000)	0.61
"0%, dosed two times (b."	( The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Sall, K, 2000)	0.6
"9 mm Hg with brinzolamide twice-daily dosing and -2."	( The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. March, WF; Ochsner, KI, 2000)	0.95
"Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months."	( The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. March, WF; Ochsner, KI, 2000)	2.02
" No differences between groups were observed preinstillation nor following dosing at 3 or 10-min postinstillation."	( Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects. Day, DG; Holmes, KT; Jenkins, JN; Stewart, JA; Stewart, WC, 2004)	0.57
" However, pain symptoms are fewer following chronic dosing and are generally characterized as mild."	( Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects. Day, DG; Holmes, KT; Jenkins, JN; Stewart, JA; Stewart, WC, 2004)	0.57
"Qualified patients at Visit 1 were placed on travoprost dosed every evening for 4 weeks and then were randomized at baseline (Visit 2) to the addition of timolol maleate or brinzolamide each given twice daily."	( The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Berta, A; Chiselita, D; Cvenkel, B; Holló, G; Izgi, B; Liehneova, I; Petkova, N; Stewart, WC; Szaflik, J; Turacli, E, )	0.58
"5%, both dosed twice daily."	( Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: a randomized clinical trial. Bergamini, MV; Dickerson, JE; Gross, RD; Hua, SY; Landry, TA; Roarty, JD; Robin, AL; Scheib, SA; Scott, H; Vijaya, L; Whitson, JT; Woodside, AM, 2008)	0.72
"5%, dosed twice daily and were followed up while receiving therapy for 6 months."	( Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Arzeno, G; Bergamini, MV; Dickerson, JE; Hua, SY; James, JE; Kaback, M; Landry, TA; Salem, C; Scoper, SV, 2008)	0.61
"To compare the effectiveness of only 1 drop of topical brinzolamide 1% with dosing every 12 hours and with no ocular hypotensive medication following clear corneal phacoemulsification surgery."	( Medical control of intraocular pressure with brinzolamide 1% after phacoemulsification. Cakmak, H; Dayanir, V; Kir, E, 2008)	0.85
"The current study reveals that 1 drop of brinzolamide 1% is sufficient to control IOP within the first 4 to 6 hours following uneventful phacoemulsification, whereas 12-hour dosing is necessary for prolonged control of IOP."	( Medical control of intraocular pressure with brinzolamide 1% after phacoemulsification. Cakmak, H; Dayanir, V; Kir, E, 2008)	0.87
"Of the 437 patients enrolled, 220 dosed Brinz/Tim whereas 217 dosed Dorz/Tim twice daily."	( The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Aung, T; Chew, P; Coote, MA; Denis, P; Filatori, I; James, J; Laganovska, G; Manni, G; Orengo-Nania, S; Sharpe, ED; Volksone, L; Zeyen, T, )	0.43
" However, their short duration of action requiring multiple daily dosing can hamper patient compliance."	( Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension. Bas, JF; Jansook, P; Kristjánsdóttir, SS; Loftsson, T; Sigurdsson, BB; Sigurdsson, HH; Stefánsson, E; Thorsteinsdóttir, M, 2010)	0.36
" For multiple dosing, rabbits were dosed twice per day with an 8-h interval between two doses, groups of rabbits were euthanized at 7, 14, and 21 days at 1 h after the last dose, and ocular tissues and plasma samples were collected."	( Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow. Jadhav, G; Kadam, RS; Kompella, UB; Ogidigben, M, 2011)	0.63
" Targeting of multiple mechanisms in combination therapies has proven effective both clinically and commercially although potential improvements with regards to efficacy, tolerability and dosing frequency remain."	( A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma. Frieman, B; Hegde, SS; Hill, CM; Jiang, L; Kintz, S; Long, DD; Marquess, DG; Purkey, H; Shaw, JP; Steinfeld, T; Wilson, MS; Wrench, K, 2013)	0.39
"2% monotherapy, all dosed 2 times per day (BID)."	( Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Aung, T; Branch, JD; Goldberg, I; Hernandez Paredes, TJ; Laganovska, G; Tsorbatzoglou, A, 2014)	0.78
"Timolol is a non-cardioselective beta blocker and has different combined ophthalmic dosage forms for treatment of glaucoma."	( A versatile HPLC method with an isocratic single mobile phase system for simultaneous determination of anti-glaucoma formulations containing timolol. El Abass, SA; Elmansi, HM; Ibrahim, FA, 2019)	0.51
"Despite the advances in the field of pharmaceutical materials and technology, topical administration remains a method of choice for the treatment of eye diseases such as glaucoma, with eye drops being a leading dosage form."	( Mucoadhesive brinzolamide-loaded nanofibers for alternative glaucoma treatment. Cegielska, O; Kogermann, K; Lorenz, K; Sajkiewicz, P; Sierakowski, M, 2022)	1.09

Role	Description
antiglaucoma drug	Any drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye.
EC 4.2.1.1 (carbonic anhydrase) inhibitor	An EC 4.2.1.* (hydro-lyases) inhibitor that interferes with the action of carbonic anhydrase (EC 4.2.1.1). Such compounds reduce the secretion of H(+) ions by the proximal kidney tubule.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
sulfonamide	An amide of a sulfonic acid RS(=O)2NR'2.
thienothiazine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	2.9849	0.0060	38.0041	19,952.5996	AID1159521
TDP1 protein	Homo sapiens (human)	Potency	0.9200	0.0008	11.3822	44.6684	AID686978
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	43.6486	0.0123	7.9835	43.2770	AID1645841
cytochrome P450 2D6	Homo sapiens (human)	Potency	38.9018	0.0010	8.3798	61.1304	AID1645840
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	0.7079	0.7079	36.9043	89.1251	AID504333
chromobox protein homolog 1	Homo sapiens (human)	Potency	100.0000	0.0060	26.1688	89.1251	AID540317
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	29.0929	5.8048	36.1306	65.1308	AID540253
snurportin-1	Homo sapiens (human)	Potency	29.0929	5.8048	36.1306	65.1308	AID540253
GTP-binding nuclear protein Ran isoform 1	Homo sapiens (human)	Potency	29.0929	5.8048	16.9962	25.9290	AID540253
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, CARBONIC ANHYDRASE IV	Mus musculus (house mouse)	IC50 (µMol)	0.0453	0.0453	0.0453	0.0453	AID977608
Carbonic anhydrase	Astrosclera willeyana	Ki	0.2780	0.0320	1.5172	9.6000	AID644379
Carbonic anhydrase	Sulfurihydrogenibium sp. YO3AOP1	Ki	0.0123	0.0045	0.1624	0.8760	AID1268964
Carbonic anhydrase	Stylophora pistillata	Ki	0.0482	0.0000	0.6867	10.0000	AID436565; AID552130
Carbonic anhydrase	Stylophora pistillata	Ki	0.1690	0.0000	0.5071	5.7100	AID552131
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Carbonic anhydrase	Helicobacter pylori 26695	Ki	0.2280	0.0200	0.5486	4.3600	AID261581; AID263638
Carbonic anhydrase 12	Homo sapiens (human)	Ki	0.0030	0.0002	1.1043	9.9000	AID1067227; AID1204091; AID1593068; AID238316; AID239126; AID239284; AID272527; AID293193; AID311032; AID327767; AID353231; AID770582; AID780321
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Carbonic anhydrase 1	Homo sapiens (human)	Ki	25.8638	0.0000	1.3726	10.0000	AID1067230; AID1142833; AID1188134; AID1190063; AID1194024; AID1195369; AID1262263; AID1268962; AID1275913; AID1287517; AID1434427; AID1453412; AID1593065; AID1605088; AID1628036; AID1796552; AID1796755; AID1796855; AID1797360; AID1797528; AID1798769; AID261579; AID263636; AID271710; AID275807; AID281082; AID300867; AID311023; AID317579; AID327758; AID349605; AID353228; AID367820; AID369271; AID414955; AID427125; AID436563; AID47725; AID47726; AID50361; AID50371; AID50374; AID552127; AID577526; AID587130; AID612725; AID644380; AID725955; AID743515; AID764719; AID770586
Carbonic anhydrase 2	Homo sapiens (human)	IC50 (µMol)	0.0242	0.0002	1.1060	8.3000	AID1200902; AID1796686; AID47746
Carbonic anhydrase 2	Homo sapiens (human)	Ki	3,634.6737	0.0000	0.7236	9.9200	AID1061069; AID1067229; AID1142834; AID1188135; AID1190064; AID1194025; AID1195370; AID1240217; AID1262264; AID1268963; AID1275912; AID1278409; AID1287518; AID1434428; AID1453413; AID1593066; AID1605089; AID1628037; AID1796552; AID1796582; AID1796687; AID1796755; AID1796855; AID1797360; AID1797528; AID1798769; AID238220; AID238255; AID238300; AID238635; AID238768; AID238787; AID238850; AID256963; AID261580; AID263049; AID263637; AID271711; AID272521; AID275808; AID281083; AID300868; AID311024; AID317580; AID327759; AID349606; AID353229; AID367821; AID369272; AID414956; AID427124; AID436564; AID437749; AID448552; AID47902; AID47915; AID47929; AID47931; AID47935; AID47939; AID47940; AID47942; AID552128; AID577527; AID587131; AID612726; AID644381; AID669115; AID725956; AID726603; AID743514; AID764718; AID770585; AID780325
Carbonic anhydrase 3	Homo sapiens (human)	Ki	110.0000	0.0002	2.0102	10.0000	AID301578; AID327760
5-hydroxytryptamine receptor 2C	Rattus norvegicus (Norway rat)	Ki	0.0030	0.0002	0.6677	10.0000	AID47929; AID47942
5-hydroxytryptamine receptor 2A	Rattus norvegicus (Norway rat)	Ki	0.0030	0.0001	0.6017	10.0000	AID47929; AID47942
Carbonic anhydrase 4	Homo sapiens (human)	IC50 (µMol)	0.0313	0.0032	0.3171	2.0000	AID1796686; AID48293
Carbonic anhydrase 4	Homo sapiens (human)	Ki	3.9500	0.0002	1.9720	9.9200	AID1605090; AID327761
Carbonic anhydrase 6	Homo sapiens (human)	Ki	0.0084	0.0001	1.4710	9.9200	AID1798769; AID275806; AID311029; AID327764; AID369273; AID552129; AID780324
Carbonic anhydrase 5A, mitochondrial	Mus musculus (house mouse)	Ki	0.0330	0.0030	0.4560	3.0000	AID1797528
5-hydroxytryptamine receptor 2B	Rattus norvegicus (Norway rat)	Ki	0.0030	0.0002	0.5909	10.0000	AID47929; AID47942
Delta-type opioid receptor	Mus musculus (house mouse)	Ki	22.5015	0.0000	0.5393	9.4000	AID1188134; AID1188135
Delta-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	0.0030	0.0000	0.6068	9.2330	AID1188135
Mu-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	45.0000	0.0000	0.3845	8.6000	AID1188134
Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)	Ki	0.0404	0.0000	1.2725	9.9000	AID1796582; AID256964; AID272523; AID311027; AID327762
Carbonic anhydrase 7	Homo sapiens (human)	Ki	0.0028	0.0002	1.3737	9.9000	AID1605091; AID238256; AID272525; AID311030; AID327765; AID764717; AID770584; AID780323
Carbonic anhydrase	Saccharomyces cerevisiae S288C	Ki	0.1140	0.0820	0.5609	8.7000	AID367822
Carbonic anhydrase	Mycobacterium tuberculosis H37Rv	Ki	0.2010	0.0120	2.7238	9.1200	AID448554
Mu-type opioid receptor	Cavia porcellus (domestic guinea pig)	Ki	0.0030	0.0000	0.2786	9.0000	AID1188135
Beta-carbonic anhydrase 1	Mycobacterium tuberculosis H37Rv	Ki	0.8390	0.0048	3.3841	9.8400	AID1798985; AID349607; AID448553
Carbonic anhydrase 2	Mycobacterium tuberculosis H37Rv	Ki	0.1270	0.0090	2.2096	9.8400	AID437750
Carbonic anhydrase 9	Homo sapiens (human)	Ki	0.0346	0.0001	0.7874	9.9000	AID1067228; AID1593067; AID1796755; AID1796855; AID1797360; AID1798769; AID238224; AID238769; AID238788; AID239048; AID239102; AID271712; AID272526; AID275809; AID281084; AID300869; AID311031; AID317581; AID327766; AID353230; AID369274; AID48296; AID48299; AID48300; AID48301; AID770583; AID780322
Carbonic anhydrase, alpha family	Hydrogenovibrio crunogenus XCL-2	Ki	0.0042	0.0025	0.3234	1.1000	AID1268965
Carbonic anhydrase	Cryptococcus neoformans var. grubii	Ki	0.0870	0.0100	0.7364	8.3470	AID669116
Carbonic anhydrase	Candida albicans SC5314	Ki	0.8430	0.0105	1.4444	8.3470	AID1799266; AID427122; AID669117
Carbonic anhydrase	Anopheles gambiae (African malaria mosquito)	Ki	0.0314	0.0098	0.5117	4.3600	AID1195371
Delta carbonic anhydrase	Conticribra weissflogii	Ki	0.1180	0.0496	0.9978	9.2000	AID1061066
Carbonic anhydrase	Nakaseomyces glabratus CBS 138	Ki	4.3500	0.0070	1.2174	9.1700	AID744415
Carbonic anhydrase 13	Homo sapiens (human)	Ki	0.0110	0.0003	1.2309	9.8000	AID780320
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Carbonic anhydrase 4	Bos taurus (cattle)	Ki	3,483,830.8042	0.0030	0.5934	9.6500	AID1796755; AID1797528; AID263050; AID48122; AID48123; AID48132; AID48280; AID48281; AID48286
Carbonic anhydrase 15	Mus musculus (house mouse)	Ki	0.0410	0.0009	1.8846	10.0000	AID1798769; AID369275
Carbonic anhydrase 13	Mus musculus (house mouse)	Ki	0.0100	0.0002	1.3974	9.9000	AID327768
Carbonic anhydrase 14	Homo sapiens (human)	Ki	0.0240	0.0002	1.5099	9.9000	AID239703; AID272529; AID293194; AID311034; AID327769; AID780319
Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)	Ki	0.0290	0.0000	1.3412	9.9700	AID1796582; AID256965; AID272524; AID311028; AID327763
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Carbonic anhydrase 2	Homo sapiens (human)	Kd	0.0001	0.0000	0.4157	5.5500	AID1200901; AID1796823
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Carbonic anhydrase	Brucella suis 1330	Kinact	0.0260	0.0170	0.8628	5.8700	AID459696
cystic fibrosis transmembrane conductance regulator ATP-binding cassette sub-family C member 7	Homo sapiens (human)	AC50	0.0398	0.0398	15.0025	50.0000	AID743267
Carbonic anhydrase 12	Homo sapiens (human)	Kinact	0.0030	0.0030	0.6674	9.6000	AID299547; AID408472
Carbonic anhydrase 1	Homo sapiens (human)	Kinact	45.0000	0.0100	0.9387	8.6000	AID299242; AID299538; AID408469
Carbonic anhydrase 2	Homo sapiens (human)	Kinact	0.0030	0.0030	0.7946	10.0000	AID299243; AID299539; AID408470
Carbonic anhydrase 4	Homo sapiens (human)	Kinact	3.9500	0.0740	2.3934	8.5900	AID300467
Carbonic anhydrase 6	Homo sapiens (human)	Kinact	0.0009	0.0009	0.7261	5.3000	AID299544
Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)	Kinact	0.0500	0.0200	0.8580	9.4000	AID299542
Carbonic anhydrase 7	Homo sapiens (human)	Kinact	0.0028	0.0002	0.2852	5.7300	AID299545
Carbonic anhydrase 9	Homo sapiens (human)	Kinact	0.0370	0.0050	0.3197	6.6700	AID299546; AID408471
Carbonic anhydrase 14	Homo sapiens (human)	Kinact	0.0240	0.0002	1.4495	8.5900	AID299549
Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)	Kinact	0.0300	0.0090	0.9231	9.0400	AID299543
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
estrous cycle	Carbonic anhydrase 12	Homo sapiens (human)
chloride ion homeostasis	Carbonic anhydrase 12	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 12	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 1	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 2	Homo sapiens (human)
angiotensin-activated signaling pathway	Carbonic anhydrase 2	Homo sapiens (human)
regulation of monoatomic anion transport	Carbonic anhydrase 2	Homo sapiens (human)
secretion	Carbonic anhydrase 2	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 2	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of dipeptide transmembrane transport	Carbonic anhydrase 2	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 2	Homo sapiens (human)
carbon dioxide transport	Carbonic anhydrase 2	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 2	Homo sapiens (human)
response to bacterium	Carbonic anhydrase 3	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 3	Homo sapiens (human)
bicarbonate transport	Carbonic anhydrase 4	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 4	Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter taste	Carbonic anhydrase 6	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 6	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 7	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 7	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 7	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 7	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 7	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 7	Homo sapiens (human)
response to hypoxia	Carbonic anhydrase 9	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 9	Homo sapiens (human)
response to xenobiotic stimulus	Carbonic anhydrase 9	Homo sapiens (human)
response to testosterone	Carbonic anhydrase 9	Homo sapiens (human)
secretion	Carbonic anhydrase 9	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 9	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 13	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 14	Homo sapiens (human)
response to bacterium	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 12	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 12	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 1	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
protein binding	Carbonic anhydrase 1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 1	Homo sapiens (human)
hydro-lyase activity	Carbonic anhydrase 1	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 2	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
protein binding	Carbonic anhydrase 2	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 2	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 3	Homo sapiens (human)
protein binding	Carbonic anhydrase 3	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 3	Homo sapiens (human)
nickel cation binding	Carbonic anhydrase 3	Homo sapiens (human)
protein binding	Carbonic anhydrase 4	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 4	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 4	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 6	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 6	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 7	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 7	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 9	Homo sapiens (human)
protein binding	Carbonic anhydrase 9	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 9	Homo sapiens (human)
molecular function activator activity	Carbonic anhydrase 9	Homo sapiens (human)
protein binding	Carbonic anhydrase 13	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 13	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 13	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 4	Bos taurus (cattle)
zinc ion binding	Carbonic anhydrase 14	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 14	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
membrane	Carbonic anhydrase 12	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
cytosol	Carbonic anhydrase 1	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 1	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
cytosol	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
myelin sheath	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 2	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
cytosol	Carbonic anhydrase 3	Homo sapiens (human)
cytosol	Carbonic anhydrase 3	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 3	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
rough endoplasmic reticulum	Carbonic anhydrase 4	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment	Carbonic anhydrase 4	Homo sapiens (human)
Golgi apparatus	Carbonic anhydrase 4	Homo sapiens (human)
trans-Golgi network	Carbonic anhydrase 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
external side of plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
cell surface	Carbonic anhydrase 4	Homo sapiens (human)
membrane	Carbonic anhydrase 4	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
transport vesicle membrane	Carbonic anhydrase 4	Homo sapiens (human)
secretory granule membrane	Carbonic anhydrase 4	Homo sapiens (human)
brush border membrane	Carbonic anhydrase 4	Homo sapiens (human)
perinuclear region of cytoplasm	Carbonic anhydrase 4	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
extracellular region	Carbonic anhydrase 6	Homo sapiens (human)
extracellular space	Carbonic anhydrase 6	Homo sapiens (human)
cytosol	Carbonic anhydrase 6	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 6	Homo sapiens (human)
extracellular space	Carbonic anhydrase 6	Homo sapiens (human)
mitochondrial matrix	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
cytosol	Carbonic anhydrase 7	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 7	Homo sapiens (human)
nucleolus	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
membrane	Carbonic anhydrase 9	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
microvillus membrane	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
cytosol	Carbonic anhydrase 13	Homo sapiens (human)
myelin sheath	Carbonic anhydrase 13	Homo sapiens (human)
intracellular membrane-bounded organelle	Carbonic anhydrase 13	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 13	Homo sapiens (human)
cytosol	Carbonic anhydrase 13	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
side of membrane	Carbonic anhydrase 4	Bos taurus (cattle)
plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
membrane	Carbonic anhydrase 14	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (435)

Assay ID	Title	Year	Journal	Article
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1434430	Inhibition of Vibrio cholerae Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID47720	Inhibitory activity against Human Carbonic anhydrase I	2002	Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7	Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.
AID587132	Inhibition of Leptonychotes weddellii alpha-carbonic anhydrase after 15 mins by CO2 hydrase assay at pH 7.5	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Purification and inhibition studies with anions and sulfonamides of an α-carbonic anhydrase from the Antarctic seal Leptonychotes weddellii.
AID1434429	Inhibition of Burkholderia pseudomallei Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID711212	Inhibition of recombinant Vibrio cholerae carbonic anhydrase expressed in Escherichia coli (DE3) preincubated for 15 mins by stopped-flow CO2 hydrase assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	DNA cloning, characterization, and inhibition studies of an α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID437750	Inhibition of full length Mycobacterium tuberculosis H37Rv recombinant carbonic anhydrase 2 encoded by RV3588c by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.
AID1142838	Inhibition of Helicobacter pylori carbonic anhydrase by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID1726079	Inhibition of Vibrio cholerae beta carbonic anhydrase pre-incubated for 15 mins prior to testing by phenol red-based stopped-flow CO2 hydration assay	2020	ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11	In Silico-Guided Identification of New Potent Inhibitors of Carbonic Anhydrases Expressed in
AID238620	Inhibitory activity against cytosolic human carbonic anhydrase I	2005	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID1188135	Inhibition of human recombinant Carbonic anhydrase 2 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID408469	Inhibition of human recombinant CA1 by stopped flow CO2 hydration assay	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID552131	Inhibition of Stylophora pistillata carbonic anhydrase 2 by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID1628036	Inhibition of full length human cytosolic carbonic anhydrase 1 preincubated for 15 mins by stop flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17	Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID780321	Inhibition of human carbonic anhydrase12 preincubated for 15 mins by stopped-flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases.
AID1200919	Inhibition of carbonic anhydrase in pigmented male Dutch-belted rabbit treated with 3% 2 x 25 uL topical dose of formulated compound in each eye after 2 to 8 hrs by pH-STAT method	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design, synthesis, and evaluation of NO-donor containing carbonic anhydrase inhibitors to lower intraocular pressure.
AID448552	Inhibition of human cloned full length carbonic anhydrase 2 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesulfonamides.
AID577531	Inhibition of Brucella suis carbonic anhydrase I by spectrophotometry at pH 8.3	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID275809	Inhibition of catalytic domain of human recombinant CA IX	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID1142834	Inhibition of human carbonic anhydrase-2 by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID408470	Inhibition of human recombinant CA2 by stopped flow CO2 hydration assay	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID166441	In vivo intraocular pressure (IOP) lowering at 30 min in normotensive rabbits after treatment with one drop (50 uL) 2% solution of CA inhibitor directly into the eye, at 5.5pH	2001	Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13	Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties.
AID764717	Inhibition of human cytosolic carbonic anhydrase 7 preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Carbonic anhydrase inhibitors: Synthesis and inhibition of the cytosolic mammalian carbonic anhydrase isoforms I, II and VII with benzene sulfonamides incorporating 4,5,6,7-tetrachlorophthalimide moiety.
AID327769	Inhibition of human full length carbonic anhydrase 14 by stopped flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID369272	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID244399	Selectivity ratio of Inhibitory constant against human carbonic anhydrase II to carbonic anhydrase IX	2005	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12	Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID1453411	Inhibition of Burkholderia pseudomallei beta-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID1188136	Inhibition of Helicobacter pylori Beta-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID1190065	Inhibition of Plasmodium falciparum Eta-carbonic anhydrase pre-incubated for 15 mins before CO2 substrate addition by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID1278409	Inhibition of human carbonic anhydrase 2 preincubated for 15 mins by CO2 hydrase stopped flow assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID272522	Inhibition of human cloned CA4 by stopped-flow CO2 hydration method	2006	Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24	Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID327767	Inhibition of human catalytic domain carbonic anhydrase 12 by stopped flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID263049	Inhibition of human CA2	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	QSAR study on topically acting sulfonamides incorporating GABA moieties: a molecular connectivity approach.
AID1809976	Solubility of compound in water	2021	Bioorganic & medicinal chemistry letters, 12-01, Volume: 53	Discovery of novel aminosaccharide-based sulfonamide derivatives as potential carbonic anhydrase II inhibitors.
AID1278410	Inhibition of Porphyromonas gingivalis gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1275913	Inhibition of human Carbonic anhydrase1 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1200925	Reduction in intraocular pressure in pigmented male Dutch-belted rabbit treated with 1% 2 x 25 uL topical dose of formulated compound in right eye and measured after 1 to 2 hrs by non-contact tonometry	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design, synthesis, and evaluation of NO-donor containing carbonic anhydrase inhibitors to lower intraocular pressure.
AID437749	Inhibition of human recombinant CA2 by stopped-flow hydration assay	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.
AID272526	Inhibition of catalytic domain of human cloned CA9 by stopped-flow CO2 hydration method	2006	Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24	Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID261581	Inhibition of Helicobacter pylori recombinant carbonic anhydrase by stopped-flow CO2 hydrase assay	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID166333	Fall of intraocular pressure (IOP) after treatment with 50 ug into normotensive rabbit at time interval 60 min at a pH of 5.5	2003	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17	Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide.
AID300870	Selectivity ratio of Ki for human cloned CA1 to Ki for human cloned catalytic domain CA9	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID256965	Inhibitory activity against human recombinant mitochondrial isozyme CA VB	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID1200901	Binding affinity to human carbonic anhydrase 2 incubated for 1 hr using labeled BODIPY558/568-acetazolamide as tracer by fluorescence polarization tight binding assay	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design, synthesis, and evaluation of NO-donor containing carbonic anhydrase inhibitors to lower intraocular pressure.
AID349605	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID369274	Inhibition of human recombinant carbonic anhydrase 9 catalytic domain by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1204106	Inhibition of recombinant Streptococcus mutans UA159 beta-carbonic anhydrase expressed in Escherichia coli Arctic cells preincubated for 15 mins by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	Sulfonamide inhibition study of the β-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans.
AID48122	Inhibitory activity against bovine carbonic anhydrase IV	2002	Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7	Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.
AID272528	Inhibition of murine CA13 by stopped-flow CO2 hydration method	2006	Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24	Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1204093	Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-2 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-9	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID317582	Selectivity for human CA9 over human CA1	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID146521	In vivo intraocular pressure lowering in Normotensive Rabbits after the administration at a pH of 5.5, at time interval 60 min	2002	Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7	Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.
AID1190064	Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID349606	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID587130	Inhibition of human carbonic anhydrase 1 after 15 mins by CO2 hydrase assay at pH 7.5	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Purification and inhibition studies with anions and sulfonamides of an α-carbonic anhydrase from the Antarctic seal Leptonychotes weddellii.
AID577526	Inhibition of human carbonic anhydrase I by spectrophotometry at pH 7.5	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID311031	Inhibition of human carbonic anhydrase 9	2007	Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13	Carbonic anhydrases as targets for medicinal chemistry.
AID299543	Inhibition of human CA5B	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID47726	Inhibitory activity against human cloned isoenzyme carbonic anhydrase II (hCA II) by esterase method	2003	Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5	Carbonic anhydrase inhibitors: inhibition of cytosolic isozymes I and II with sulfamide derivatives.
AID1287520	Inhibition of recombinant Enterobacter sp. B13 beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID427122	Inhibition of Candida albicans recombinant Nce103 by stopped-flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID48281	Inhibitory activity against bovine lung microsomes carbonic anhydrase isozyme IV (bCA IV).	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring?
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1268963	Inhibition of recombinant human carbonic anhydrase-2 by stopped flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID1194024	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID299243	Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID272525	Inhibition of human cloned CA7 by stopped-flow CO2 hydration method	2006	Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24	Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID299551	Inhibition of Helicobacter pylori beta CA	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID353229	Inhibition of human recombinant CA2 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Inhibition of carbonic anhydrase isozymes with benzene sulfonamides incorporating thio, sulfinyl and sulfonyl glycoside moieties.
AID780322	Inhibition of human carbonic anhydrase9 preincubated for 15 mins by stopped-flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases.
AID327766	Inhibition of human catalytic domain carbonic anhydrase 9 by stopped flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID238567	Ki value against murine carbonic anhydrase XIII was determined; (not tested)	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID1262263	Inhibition of human CA1 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID50361	Compound was evaluated for binding affinity against human carbonic anhydrase II (hCA -II)	2001	Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13	Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties.
AID293193	Inhibition of human recombinant CA12 by CO2 hydration assay	2007	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4	Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides.
AID261579	Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase assay	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID1142836	Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia-1 carbonic anhydrase-1 assessed as CO2 hydrase activity by stopped-flow assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID243011	Selectivity ratio against human carbonic anhydrases II and XII	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID770586	Inhibition of human cytosolic carbonic anhydrase 1 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID1195370	Inhibition of human carbonic anhydrase 2 pre-incubated for 15 mins by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID1194026	Inhibition of recombinant Methanosarcina thermophila gamma-carbonic anhydrase by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID300869	Inhibition of human cloned catalytic domain CA9 by CO2 hydration method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID770584	Inhibition of human cytosolic carbonic anhydrase 7 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID612731	Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 1 at pH 8.3 by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID146519	In vivo intraocular pressure lowering in Normotensive Rabbits after the administration at a pH of 5.5, at time interval 0 min	2002	Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7	Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.
AID47940	Inhibitory activity against human carbonic anhydrase II	2004	Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID726232	Inhibition of Trypanosoma cruzi CL Brener recombinant alpha-carbonic anhydrase expressed in insect Sf9 cell Baculovirus system by stopped flow CO2 hydration assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID1195369	Inhibition of human carbonic anhydrase 1 pre-incubated for 15 mins by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID272523	Inhibition of human cloned CA5A by stopped-flow CO2 hydration method	2006	Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24	Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID48123	Inhibitory activity against human cloned Carbonic Anhydrase isozyme(bCA IV)	2002	Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12	Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails.
AID644380	Inhibition of human recombinant carbonic anhydrase 1 after 15 mins by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID1200917	Inhibition of carbonic anhydrase in pigmented male Dutch-belted rabbit treated with 1% 2 x 25 uL topical dose of formulated compound in each eye after 2 to 8 hrs by pH-STAT method	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design, synthesis, and evaluation of NO-donor containing carbonic anhydrase inhibitors to lower intraocular pressure.
AID47942	Inhibitory activity against human carbonic anhydrase II	2003	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17	Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide.
AID1593067	Inhibition of human CA 9 catalytic domain	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines.
AID1061169	Inhibition of recombinant Methanosarcina thermophila gamma-CA CAM by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
AID299541	Inhibition of human CA4	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID166568	In vivo intraocular pressure (IOP) lowering at 90 min in normotensive rabbits after treatment with one drop (50 uL) 2% solution of CA inhibitor directly into the eye, at 5.5pH	2001	Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13	Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties.
AID166335	Fall of intraocular pressure (IOP) after treatment with 50 ug into normotensive rabbit at time interval 90 min at a pH of 5.5	2003	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17	Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide.
AID1605090	Inhibition of recombinant human carbonic anhydrase 4 incubated for 6 hrs prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Potent Dual-Tailed Benzenesulfonamide Inhibitors of Human Carbonic Anhydrases Implicated in Glaucoma and in Vivo Profiling of Their Intraocular Pressure-Lowering Action.
AID778725	Inhibition of recombinant Leishmania donovani chagasi beta-carbonic anhydrase expressed in baculovirus infected insect Sf9 cells incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Leishmania donovani chagasi, the protozoan parasite responsible for leishmaniasis.
AID238753	Inhibitory activity against Carbonic anhydrase I	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID369271	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID414961	Inhibition of Mycobacterium tuberculosis H37Rv recombinant beta-carbonic anhydrase 1 expressed in Escherichia coli BL21 by stopped flow CO2 hydration method	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID780318	Selectivity ratio of Ki for human carbonic anhydrase9 to Ki for human carbonic anhydrase2	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases.
AID238224	Inhibitory constant against human Carbonic anhydrase IX	2005	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12	Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID1593068	Inhibition of human CA 12 catalytic domain	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines.
AID1605088	Inhibition of recombinant human carbonic anhydrase 1 incubated for 6 hrs prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Potent Dual-Tailed Benzenesulfonamide Inhibitors of Human Carbonic Anhydrases Implicated in Glaucoma and in Vivo Profiling of Their Intraocular Pressure-Lowering Action.
AID238850	Inhibitory activity against human carbonic anhydrase II	2005	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17	Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.
AID327764	Inhibition of human full length carbonic anhydrase 6 by stopped flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID353230	Inhibition of human recombinant CA9 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Inhibition of carbonic anhydrase isozymes with benzene sulfonamides incorporating thio, sulfinyl and sulfonyl glycoside moieties.
AID238984	Inhibitory activity against human carbonic anhydrase I expressed in Escherichia coli BL21; not tested	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID238316	Ki value against human carbonic anhydrase XII (hCA XII)	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID1453410	Inhibition of Francisella tularensis beta-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID299538	Inhibition of human CA1	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID1240215	Inhibition of Pseudoalteromonas haloplanktis gamma carbonic anhydrase by CO2 hydration assay	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID1204092	Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-1 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-9	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID238300	Ki value against human carbonic anhydrase II (hCA II)	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1278412	Inhibition of Pseudoalteromonas haloplanktis gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID644379	Inhibition of GST-tagged astrosclera willeyana Astrosclerin-3 expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID299547	Inhibition of human CA12	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID414956	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration method	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID47935	Inhibitory activity against human recombinant carbonic anhydrase II	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring?
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID414955	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration method	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID47929	Inhibition of human carbonic anhydrase II	2004	Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1	Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits.
AID47915	Compound was evaluated for binding affinity against bovine carbonic anhydrase IV (bCA IV)	2001	Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13	Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties.
AID1190063	Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID1142837	Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia-1 carbonic anhydrase-2 assessed as CO2 hydrase activity by stopped-flow assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID281086	Selectivity ratio of human CA9 over human CA2	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID1593065	Inhibition of full length human CA 1	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines.
AID281085	Selectivity ratio of human CA9 over human CA1	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID317581	Inhibition of human CA9 catalytic domain by CO2 hydration method	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID780320	Inhibition of human carbonic anhydrase13 preincubated for 15 mins by stopped-flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases.
AID47746	Concentration which produces 50% inhibition of human Carbonic anhydrase II	2002	Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4	Structural aspects of isozyme selectivity in the binding of inhibitors to carbonic anhydrases II and IV.
AID311024	Inhibition of human carbonic anhydrase 2	2007	Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13	Carbonic anhydrases as targets for medicinal chemistry.
AID367820	Inhibition of human recombinant CA1 by stopped-flow CO2 hydrase assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID726603	Inhibition of human recombinant carbonic anhydrase 2 by dansylamide (DNSA) competition assay	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma.
AID725956	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID166565	In vivo intraocular pressure (IOP) lowering at 60 min in normotensive rabbits after treatment with one drop (50 uL) 2% solution of CA inhibitor directly into the eye, at 5.5pH	2001	Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13	Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties.
AID300868	Inhibition of human cloned CA2 by CO2 hydration method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID281084	Inhibition of catalytic domain of human recombinant isozyme CA9 by CO2 hydration method	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID1061069	Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID239126	Inhibitory constant against catalytic domain of human carbonic anhydrase XII	2005	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.
AID1275912	Inhibition of human Carbonic anhydrase2 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID369275	Inhibition of mouse recombinant carbonic anhydrase 15 by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1061067	Inhibition of Porphyromonas gingivalis recombinant gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID644381	Inhibition of human recombinant carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID311032	Inhibition of human carbonic anhydrase 12	2007	Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13	Carbonic anhydrases as targets for medicinal chemistry.
AID271711	Inhibition of human cloned CA2 by CO2 hydration method	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID743512	Inhibition of Sulfurihydrogenibium yellowstonense YO3AOP1 recombinant carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay	2013	Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6	The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID1204091	Inhibition of recombinant human transmembrane, tumor-associated form of carbonic anhydrase-12 preincubated for 15 mins by stopped flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID299548	Inhibition of mouse CA13	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID1434428	Inhibition of human carbonic anhydrase 2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID552129	Inhibition of human recombinant CA6 by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID408472	Inhibition of human cloned CA12 catalytic domain by stopped flow CO2 hydration assay	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID238686	Ki value against human carbonic anhydrase I; ND means not determined	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID1809108	Solubility of the compound	2021	Bioorganic & medicinal chemistry letters, 11-01, Volume: 51	Novel carbohydrate-based sulfonamide derivatives as selective carbonic anhydrase II inhibitors: Synthesis, biological and molecular docking analysis.
AID271712	Inhibition of human cloned CA9 catalytic domain by CO2 hydration method	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID1061170	Inhibition of Porphyromonas gingivalis gamma-carbonic anhydrase expressed in Escherichia coli preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
AID764718	Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Carbonic anhydrase inhibitors: Synthesis and inhibition of the cytosolic mammalian carbonic anhydrase isoforms I, II and VII with benzene sulfonamides incorporating 4,5,6,7-tetrachlorophthalimide moiety.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID48301	Inhibitory activity against human carbonic anhydrase IX	2004	Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID317579	Inhibition of human cloned CA1 by CO2 hydration method	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID239703	Inhibitory constant against human carbonic anhydrase XIV in CO2 hydrase assay	2005	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.
AID1278411	Inhibition of Nostoc commune gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1200902	Inhibition of human carbonic anhydrase 2 assessed as reduction in enzyme activity incubated for 30 mins by fluorescence polarization assay	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design, synthesis, and evaluation of NO-donor containing carbonic anhydrase inhibitors to lower intraocular pressure.
AID744415	Inhibition of recombinant full length Candida glabrata NCE103 expressed in Escherichia coli BL21 preincubated for 15 mins by stopped-flow CO2 hydrase assay	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Carbonic anhydrase inhibitors: inhibition of the β-class enzyme from the pathogenic yeast Candida glabrata with sulfonamides, sulfamates and sulfamides.
AID327760	Inhibition of human full length carbonic anhydrase 3 by stopped flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID166438	In vivo intraocular pressure (IOP) lowering at 120 min in normotensive rabbits after treatment with one drop (50 uL) 2% solution of CA inhibitor directly into the eye, at 5.5pH	2001	Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13	Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties.
AID261582	Selectivity ratio for human carbonic anhydrase 2 over Helicobacter pylori carbonic anhydrase	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID50374	Inhibitory activity against human recombinant carbonic anhydrase I (CA1)	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route.
AID238256	Ki value against human carbonic anhydrase VII	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID238413	Inhibitory constant against human Carbonic anhydrase I; NT, Not tested	2005	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12	Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID436565	Inhibition of cloned Stylophora pistillata alpha-CA expressed in human HEK293 cells by stopped-flow CO2 assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID243098	Ratio of inhibitory activity of human cytosolic carbonic anhydrase II to tumor associated carbonic anhydrase IX	2005	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID271710	Inhibition of human cloned CA1 by CO2 hydration method	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID1061068	Inhibition of Leishmania donovani chagasi recombinant beta-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID275807	Inhibition of human recombinant cytosolic isozyme CA I by stopped-flow CO2 hydrase method	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID48286	Inhibitory activity against Carbonic anhydrase IV isolated from bovine lung	2003	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17	Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide.
AID48300	Inhibitory activity against human cloned carbonic anhydrase isozyme IX, by CO2 hydrase assay method.	2003	Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.
AID1142833	Inhibition of human carbonic anhydrase-1 by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID47902	Inhibitory activity against human recombinant carbonic anhydrase II (CA2)	2002	Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12	Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails.
AID743514	Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by CO2 hydration stopped-flow assay	2013	Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6	The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID239102	Inhibitory constant against catalytic domain of human carbonic anhydrase IX	2005	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.
AID1194025	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID1291363	Inhibition of recombinant Vibrio cholerae gamma-carbonic anhydrase preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8	Comparison of the sulfonamide inhibition profiles of the α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID47715	Inhibition constant of compound was determined against human cloned carbonic anhydrase I; Not tested	2003	Journal of medicinal chemistry, May-22, Volume: 46, Issue:11	Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID1268965	Inhibition of recombinant Thiomicrospira crunogena XCL-2 carbonic anhydrase by stopped flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID311027	Inhibition of human carbonic anhydrase 5A	2007	Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13	Carbonic anhydrases as targets for medicinal chemistry.
AID47725	Inhibitory activity against Human Carbonic anhydrase II	2002	Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7	Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.
AID1067225	Selectivity ratio of Ki for human transmembrane carbonic anhydrase 2 to Ki for human cytosolic carbonic anhydrase 12	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID669119	Inhibition of GST-tagged Malassezia globosa ATCC 96807/CBS 7966 MG-CA expressed in Escherichia coli BL21(DE3) cells preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID311028	Inhibition of human carbonic anhydrase 5B	2007	Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13	Carbonic anhydrases as targets for medicinal chemistry.
AID408471	Inhibition of human cloned CA9 catalytic domain by stopped flow CO2 hydration assay	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID272524	Inhibition of human cloned CA5B by stopped-flow CO2 hydration method	2006	Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24	Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID311033	Inhibition of mouse carbonic anhydrase 13	2007	Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13	Carbonic anhydrases as targets for medicinal chemistry.
AID327768	Inhibition of mouse full length carbonic anhydrase 13 by stopped flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID1188134	Inhibition of human recombinant Carbonic anhydrase 1 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID48299	Inhibition constant determined against catalytic domain of human cloned carbonic anhydrase IX	2003	Journal of medicinal chemistry, May-22, Volume: 46, Issue:11	Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID48103	Binding affinity against Carbonic anhydrase II	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.
AID50364	Inhibition of human carbonic anhydrase I	2004	Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1	Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits.
AID669115	Inhibition of human carbonic anhydrase 2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID238746	Ki value against hCA I; ND means not determined	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311030	Inhibition of human carbonic anhydrase 7	2007	Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13	Carbonic anhydrases as targets for medicinal chemistry.
AID1593066	Inhibition of full length human CA 2	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines.
AID436564	Inhibition of human recombinant CA2 by stopped-flow CO2 assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID299242	Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID1287519	Inhibition of Vibrio cholerae beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID50371	Inhibitory activity against human cloned carbonic anhydrase isozyme I by esterase assay method.	2003	Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.
AID764719	Inhibition of human cytosolic carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Carbonic anhydrase inhibitors: Synthesis and inhibition of the cytosolic mammalian carbonic anhydrase isoforms I, II and VII with benzene sulfonamides incorporating 4,5,6,7-tetrachlorophthalimide moiety.
AID770581	Selectivity ratio of Ki for human carbonic anhydrase 2 to Ki for human carbonic anhydrase 9	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID436563	Inhibition of human recombinant CA1 by stopped-flow CO2 assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID48132	Inhibition constant against bovine Carbonic anhydrase IV, isolated from lung microsomes	2003	Journal of medicinal chemistry, May-22, Volume: 46, Issue:11	Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID577527	Inhibition of human carbonic anhydrase II by spectrophotometry at pH 7.5	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID256964	Inhibitory activity against human recombinant mitochondrial isozyme CA VA	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID327761	Inhibition of human full length carbonic anhydrase 4 by stopped flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID353228	Inhibition of human recombinant CA1 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Inhibition of carbonic anhydrase isozymes with benzene sulfonamides incorporating thio, sulfinyl and sulfonyl glycoside moieties.
AID299545	Inhibition of human CA7	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID146520	In vivo intraocular pressure lowering in Normotensive Rabbits after the administration at a pH of 5.5, at time interval 30 min	2002	Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7	Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.
AID1628038	Inhibition of recombinant Plasmodium falciparum eta-carbonic anhydrase (181 to 538 residues) expressed in Escherichia coli artic express (DE3) preincubated for 15 mins by stop flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17	Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID281083	Inhibition of human recombinant isozyme CA2 by CO2 hydration method	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID271714	Selectivity for human CA9 over CA2	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID1188137	Inhibition of Porphyromonas gingivalis Beta-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID1067227	Inhibition of human transmembrane carbonic anhydrase 12 by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID311023	Inhibition of human carbonic anhydrase 1	2007	Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13	Carbonic anhydrases as targets for medicinal chemistry.
AID1278413	Inhibition of recombinant Colwellia psychrerythraea gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID743515	Inhibition of human recombinant carbonic anhydrase 1 preincubated for 15 mins by CO2 hydration stopped-flow assay	2013	Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6	The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID238769	Inhibitory activity against Carbonic anhydrase IX	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID349608	Inhibition of full length Mycobacterium tuberculosis H37Rv recombinant carbonic anhydrase 3 expressed in Escherichia coli BL21 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID1240216	Inhibition of Methanosarcina thermophila recombinant gamma carbonic anhydrase by stopped flow CO2 hydrase assay method	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID300871	Selectivity ratio of Ki for human cloned CA1 to Ki for human cloned catalytic domain CA9	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID587131	Inhibition of human carbonic anhydrase 2 after 15 mins by CO2 hydrase assay at pH 7.5	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Purification and inhibition studies with anions and sulfonamides of an α-carbonic anhydrase from the Antarctic seal Leptonychotes weddellii.
AID669117	Inhibition of Candida albicans CaNce103 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID669116	Inhibition of Cryptococcus neoformans Can2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID770582	Inhibition of human membrane bound carbonic anhydrase 12 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID299544	Inhibition of human CA6	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID1204094	Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-1 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-12	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID272520	Inhibition of human cloned CA1 by stopped-flow CO2 hydration method	2006	Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24	Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1188138	Inhibition of Porphyromonas gingivalis Gamma-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID369273	Inhibition of human full length recombinant carbonic anhydrase 6 by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID552128	Inhibition of human recombinant CA2 by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID299552	Inhibition of Methanosarcina thermophila gamma CA	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID367821	Inhibition of human recombinant CA2 by stopped-flow CO2 hydrase assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID238787	Inhibitory activity against human carbonic anhydrase II expressed in Escherichia coli BL21	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID448553	Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase Rv1284 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesulfonamides.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID263637	Inhibition of human recombinant CA2	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID427125	Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase method	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID238255	Ki value against human carbonic anhydrase II	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID239284	Inhibitory activity against catalytic domain of human carbonic anhydrase XII	2005	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17	Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.
AID577530	Inhibition of Brucella suis carbonic anhydrase II by spectrophotometry at pH 8.3	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID300867	Inhibition of human cloned CA1 by CO2 hydration method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID1067229	Inhibition of human cytosolic carbonic anhydrase 2 by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID552130	Inhibition of Stylophora pistillata carbonic anhydrase by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID299542	Inhibition of human CA5A	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID166196	Fall of intraocular pressure (IOP) after treatment with 50 ug into normotensive rabbit at time interval 240 min at a pH of 5.5	2003	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17	Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide.
AID239048	Inhibitory activity against membrane bound tumor associated human carbonic anhydrase IX	2005	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID1240217	Inhibition of human recombinant carbonic anhydrase-2 by stopped flow CO2 hydrase assay method	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID166435	In vivo intraocular pressure (IOP) lowering at 0 min in normotensive rabbits after treatment with one drop (50 uL) 2% solution of CA inhibitor directly into the eye, at 5.5pH	2001	Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13	Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties.
AID1195371	Inhibition of Anopheles gambiae carbonic anhydrase pre-incubated for 15 mins by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID272529	Inhibition of human cloned CA14 by stopped-flow CO2 hydration method	2006	Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24	Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID770585	Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID780319	Inhibition of human carbonic anhydrase14 preincubated for 15 mins by stopped-flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases.
AID311026	Inhibition of human carbonic anhydrase 4	2007	Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13	Carbonic anhydrases as targets for medicinal chemistry.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID725955	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1067226	Selectivity ratio of Ki for human transmembrane carbonic anhydrase 2 to Ki for human cytosolic carbonic anhydrase 9	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID1262267	Inhibition of Chionodraco hamatus alphaCA incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID1262264	Inhibition of human CA2 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID299540	Inhibition of human CA3	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID612726	Inhibition of human recombinant carbonic anhydrase 2 at pH 7.5 by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID327759	Inhibition of human full length carbonic anhydrase 2 by stopped flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID238220	Inhibitory constant against human Carbonic anhydrase II	2005	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12	Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID1061066	Inhibition of Thalassiosira weissflogii delta carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID770583	Inhibition of human membrane bound carbonic anhydrase 9 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID780324	Inhibition of human carbonic anhydrase6 preincubated for 15 mins by stopped-flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases.
AID612725	Inhibition of human recombinant carbonic anhydrase 1 at pH 7.5 by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID244127	Ratio of Ki for human carbonic anhydrases II and IX	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID48280	Inhibitory activity against bovine carbonic anhydrase isozyme IV isolated from bovine lung microsomes, by esterase assay method.	2003	Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.
AID48293	Concentration which produces 50% Inhibition of human Carbonic anhydrase IV	2002	Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4	Structural aspects of isozyme selectivity in the binding of inhibitors to carbonic anhydrases II and IV.
AID272527	Inhibition of catalytic domain of human cloned CA12 by stopped-flow CO2 hydration method	2006	Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24	Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID448554	Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase Rv3273 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17	Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesulfonamides.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID299250	Inhibition of Helicobacter pylori beta carbonic anhydrase by stopped-flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID1200926	Reduction in intraocular pressure unilaterally lasered ocular hypertensive cynomolgus monkey treated with 1% 2 x 25 uL topical dose of formulated compound in right eye and measured after 2 hrs by ocular hypertension primate tonometry	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design, synthesis, and evaluation of NO-donor containing carbonic anhydrase inhibitors to lower intraocular pressure.
AID299249	Inhibition of Helicobacter pylori alpha carbonic anhydrase by stopped-flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID311029	Inhibition of human carbonic anhydrase 6	2007	Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13	Carbonic anhydrases as targets for medicinal chemistry.
AID275808	Inhibition of human recombinant cytosolic isozyme CA II by stopped-flow CO2 hydrase method	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID238788	Inhibitory activity against human carbonic anhydrase IX expressed in Escherichia coli BL21	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID1200918	Inhibition of carbonic anhydrase in pigmented male Dutch-belted rabbit treated with 2% 2 x 25 uL topical dose of formulated compound in each eye after 2 to 8 hrs by pH-STAT method	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design, synthesis, and evaluation of NO-donor containing carbonic anhydrase inhibitors to lower intraocular pressure.
AID238635	Inhibitory activity against cytosolic human carbonic anhydrase II	2005	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID281082	Inhibition of human recombinant isozyme CA1 by CO2 hydration method	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID299550	Inhibition of Helicobacter pylori alpha CA	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID317580	Inhibition of human cloned CA2 by CO2 hydration method	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1434427	Inhibition of recombinant human carbonic anhydrase 1 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID233702	Selectivity ratio, inhibition (Ki) of human carbonic anhydrase IX compared to human carbonic anhydrase II	2004	Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9	Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1204095	Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-2 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-12	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID311025	Inhibition of human carbonic anhydrase 3	2007	Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13	Carbonic anhydrases as targets for medicinal chemistry.
AID256963	Inhibitory activity against human recombinant cytosolic CA2	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID299549	Inhibition of human CA14	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID1194028	Inhibition of recombinant Nostoc commune gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID299539	Inhibition of human CA2	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID367822	Inhibition of Saccharomyces cerevisiae recombinant CA expressed in Escherichia coli by stopped-flow CO2 hydrase assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID263638	Inhibition of Helicobacter pylori recombinant CA	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID299546	Inhibition of human CA9 catalytic domain	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID1194027	Inhibition of recombinant Porphyromonas gingivalis gamma-carbonic anhydrase by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID272521	Inhibition of human cloned CA2 by stopped-flow CO2 hydration method	2006	Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24	Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID327763	Inhibition of human full length carbonic anhydrase 5B by stopped flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID48296	Inhibitory activity against human tumor-associated transmembrane carbonic anhydrase IX.	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Carbonic anhydrase inhibitors: the first QSAR study on inhibition of tumor-associated isoenzyme IX with aromatic and heterocyclic sulfonamides.
AID353231	Inhibition of human recombinant CA12 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8	Inhibition of carbonic anhydrase isozymes with benzene sulfonamides incorporating thio, sulfinyl and sulfonyl glycoside moieties.
AID238768	Inhibitory activity against Carbonic anhydrase II	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID1605089	Inhibition of recombinant human carbonic anhydrase 2 incubated for 6 hrs prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Potent Dual-Tailed Benzenesulfonamide Inhibitors of Human Carbonic Anhydrases Implicated in Glaucoma and in Vivo Profiling of Their Intraocular Pressure-Lowering Action.
AID1268964	Inhibition of recombinant Sulfurihydrogenibium yellowstonense YO3AOP1 carbonic anhydrase by stopped flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID311034	Inhibition of human carbonic anhydrase 14	2007	Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13	Carbonic anhydrases as targets for medicinal chemistry.
AID1453413	Inhibition of human carbonic anhydrase-2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID1200903	Solubility of the compound	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	Design, synthesis, and evaluation of NO-donor containing carbonic anhydrase inhibitors to lower intraocular pressure.
AID427123	Inhibition of Cryptococcus neoformans recombinant Can2 by stopped-flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID47931	Inhibition constant (Ki) against human cloned carbonic anhydrase II (CAH)	2003	Journal of medicinal chemistry, May-22, Volume: 46, Issue:11	Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID743513	Inhibition of Helicobacter pylori recombinant alpha carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay	2013	Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6	The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID317583	Selectivity for human CA9 over human CA2	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID275806	Inhibition of full length human recombinant CA VI	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID349607	Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase 1 encoded by Rv1284 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID166198	Fall of intraocular pressure (IOP) after treatment with 50 ug into normotensive rabbit at time interval 30 min at a pH of 5.5	2003	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17	Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide.
AID146522	In vivo intraocular pressure lowering in Normotensive Rabbits after the administration at a pH of 5.5, at time interval 90 min	2002	Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7	Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.
AID1240214	Inhibition of Nostoc commune gamma carbonic anhydrase by CO2 hydration assay	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID612732	Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 2 at pH 8.3 by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID263639	Selectivity for Helicobacter pylori recombinant CA over human recombinant CA2	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID300467	Inhibition of human recombinant full length CA4 by stopped-flow technique	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-ray crystallographic studies.
AID1275910	Inhibition of Vibrio cholerae beta-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID271713	Selectivity for human CA9 over CA1	2006	Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22	A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID1067228	Inhibition of human transmembrane carbonic anhydrase 9 by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID293194	Inhibition of human recombinant CA14 by CO2 hydration assay	2007	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4	Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides.
AID327765	Inhibition of human full length carbonic anhydrase 7 by stopped flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID1262266	Inhibition of weddell seal alphaCA incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID327762	Inhibition of human full length carbonic anhydrase 5A by stopped flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID780325	Inhibition of human carbonic anhydrase2 preincubated for 15 mins by stopped-flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases.
AID301578	Inhibition of human recombinant CA 3 assessed as CO2 hydration by stopped flow kinetic assay	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides.
AID1605091	Inhibition of recombinant human carbonic anhydrase 7 incubated for 6 hrs prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Potent Dual-Tailed Benzenesulfonamide Inhibitors of Human Carbonic Anhydrases Implicated in Glaucoma and in Vivo Profiling of Their Intraocular Pressure-Lowering Action.
AID552127	Inhibition of human recombinant CA1 by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID1275911	Inhibition of Vibrio cholerae alpha-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID263636	Inhibition of human recombinant CA1	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID1287517	Inhibition of human carbonic anhydrase 1 incubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID1287518	Inhibition of human carbonic anhydrase 2 incubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID327758	Inhibition of human full length carbonic anhydrase 1 by stopped flow CO2 hydrase assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID1268962	Inhibition of recombinant human carbonic anhydrase-1 by stopped flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID427124	Inhibition of Helicobacter pylori beta-carbonic anhydrase by stopped-flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID1067230	Inhibition of human cytosolic carbonic anhydrase 1 by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID1453412	Inhibition of human carbonic anhydrase-1 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID263050	Inhibition of bovine CA4	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	QSAR study on topically acting sulfonamides incorporating GABA moieties: a molecular connectivity approach.
AID47939	Inhibitory activity against human recombinant carbonic anhydrase II (CA2)	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route.
AID1628037	Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stop flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17	Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID459696	Inhibition of Brucella suis CA1 expressed in Escherichia coli BL21(DE3) by stopped-flow CO2-hydration assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis.
AID780323	Inhibition of human carbonic anhydrase7 preincubated for 15 mins by stopped-flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases.
AID261580	Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydrase assay	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1346202	Human carbonic anhydrase 7 (4.2.1.1 Carbonate dehydratases)	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID1345957	Human carbonic anhydrase 14 (4.2.1.1 Carbonate dehydratases)	1992	The Journal of biological chemistry, Dec-15, Volume: 267, Issue:35	Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters.
AID1346210	Human carbonic anhydrase 12 (4.2.1.1 Carbonate dehydratases)	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID1345928	Human carbonic anhydrase 1 (4.2.1.1 Carbonate dehydratases)	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1798769	CA Inhibition Assay from Article 10.1021/jm801267c: \\Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.\\	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1796686	CA Inhibition Assay from Article 10.1016/s0968-0896(00)00026-2: \\2H-Thieno[3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides as ocular hypotensive agents: synthesis, carbonic anhydrase inhibition and evaluation in the rabbit.\\	2000	Bioorganic & medicinal chemistry, May, Volume: 8, Issue:5	2H-Thieno[3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides as ocular hypotensive agents: synthesis, carbonic anhydrase inhibition and evaluation in the rabbit.
AID1796552	CA Inhibition Assay from Article 10.1021/jm0512600: \\Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.\\	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID1796755	CA Inhibition Assay from Article 10.1021/jm021123s: \\Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.\\	2003	Journal of medicinal chemistry, May-22, Volume: 46, Issue:11	Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID1796855	CA Inhibition Assay from Article 10.1021/jm0494826: \\Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.\\	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID1798985	CA Inhibition Assay from Article 10.1021/jm9000488: \\Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.\\	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID1797360	CA Inhibition Assay from Article 10.1021/jm061320h: \\Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.\\	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID1797528	Esterase Assay from Article 10.1021/jm031057+: \\Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.\\	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID1796582	CA Inhibition Assay from Article 10.1021/jm050483n: \\Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.\\	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID1799266	CA Inhibition Assay from Article 10.1016/j.bmc.2009.05.002: \\Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.\\	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID1798982	CA Inhibition Assay from Article 10.1021/jm9003126: \\Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.\\	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID1796823	In Vitro Binding for Human Carbonic Anhydrase II from Article 10.1002/pro.5560071201: \\Structural analysis of inhibitor binding to human carbonic anhydrase II.\\	1998	Protein science : a publication of the Protein Society, Dec, Volume: 7, Issue:12	Structural analysis of inhibitor binding to human carbonic anhydrase II.
AID1796687	In vitro binding of inhibitor to hCA-II from Article 10.1016/s0968-0896(00)00026-2: \\2H-Thieno[3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides as ocular hypotensive agents: synthesis, carbonic anhydrase inhibition and evaluation in the rabbit.	2000	Bioorganic & medicinal chemistry, May, Volume: 8, Issue:5	2H-Thieno[3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides as ocular hypotensive agents: synthesis, carbonic anhydrase inhibition and evaluation in the rabbit.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	1998	Protein science : a publication of the Protein Society, Mar, Volume: 7, Issue:3	Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isozyme-drug discrimination.
AID1811	Experimentally measured binding affinity data derived from PDB	1998	Protein science : a publication of the Protein Society, Mar, Volume: 7, Issue:3	Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isozyme-drug discrimination.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	8 (2.41)	18.2507
2000's	124 (37.35)	29.6817
2010's	152 (45.78)	24.3611
2020's	48 (14.46)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	86 (24.57%)	5.53%
Reviews	25 (7.14%)	6.00%
Case Studies	24 (6.86%)	4.05%
Observational	2 (0.57%)	0.25%
Other	213 (60.86%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (60)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
[NCT01111890]	Phase 4	70 participants (Actual)	Interventional	2010-04-30	Completed
Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy [NCT03542006]	Phase 2	35 participants (Anticipated)	Interventional	2018-06-01	Not yet recruiting
Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome [NCT01312402]	Phase 4	5 participants (Actual)	Interventional	2011-01-31	Completed
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma [NCT03966560]	Phase 4	96 participants (Actual)	Interventional	2014-01-31	Completed
Comparison of the Effects of Latanoprost(0.005%) and Brinzolamide(1.0%) on Intraocular Pressure in Primary Open-angle Glaucoma and Ocular Hypertension [NCT01084902]		130 participants (Actual)	Interventional	2010-02-28	Active, not recruiting
A Multicentre, Double Blind, Active Controlled, Parallel Group, Two Arm, Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension (Manufactured by Indoco Remedies Ltd. for Watson Pharma Pvt Ltd.), to Brinzolamide (Azopt® [NCT02512042]	Phase 3	973 participants (Actual)	Interventional	2015-04-30	Completed
24-hr Intraocular Pressure Control With Brinzolamide 1% / Brimonidine 0.2% Ophthalmic Suspension vs Vehicle [NCT02770248]	Phase 4	162 participants (Actual)	Interventional	2016-05-23	Completed
Stop Retinal Ganglion Cell Dysfunction Study [NCT02390284]	Phase 3	500 participants (Anticipated)	Interventional	2015-09-30	Active, not recruiting
Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma [NCT01310777]	Phase 3	771 participants (Actual)	Interventional	2011-05-31	Completed
A Three-Month, Randomized, Double-Masked, Parallel-Group Study With a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Thr [NCT01297920]	Phase 3	1,062 participants (Actual)	Interventional	2011-03-31	Completed
Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (AZARGA®) to Ocular Hypertensive or Glaucoma Patients Uncontrolled on Prostaglandin Monotherapy [NCT01263444]	Phase 4	47 participants (Actual)	Interventional	2011-03-31	Completed
Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide Ophthalmic Suspension 1% to Azopt® in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes [NCT04024072]	Phase 3	495 participants (Actual)	Interventional	2019-06-24	Completed
Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs [NCT00675207]	Phase 4	120 participants (Actual)	Interventional	2006-01-31	Completed
Safety and IOP-Lowering Efficacy of Brinzolamide/Brimonidine Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma and/or Ocular Hypertension [NCT00961649]	Phase 2	195 participants (Actual)	Interventional	2009-10-31	Terminated
A BIOEQUIVALENCE STUDY OF THE GENERIC BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION COMPARED TO REFERENCE LISTED DRUG AZOPT® (BRINZOLAMIDE) OPHTHALMIC SUSPENSION 1% IN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION [NCT03896633]	Phase 1/Phase 2	637 participants (Actual)	Interventional	2018-02-28	Completed
[NCT01722604]	Phase 3	258 participants (Actual)	Interventional	2012-01-31	Completed
Efficacy and Safety of Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension [NCT02339584]	Phase 3	493 participants (Actual)	Interventional	2015-04-14	Completed
The Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (Azarga®) to Prostaglandin Monotherapy [NCT00966576]	Phase 4	47 participants (Actual)	Interventional	2009-07-31	Completed
Quality of 24-hour Intraocular Pressure Control Obtained With the Brinzolamide/Timolol Fixed Combination Compared With the Brimonidine/Timolol Fixed Combination When Added to Travoprost Monotherapy in Subjects With Open-angle Glaucoma [NCT00981786]	Phase 4	51 participants (Actual)	Interventional	2009-08-31	Completed
A Double-Masked, Parallel-Group, Efficacy and Safety Study of Brinzolamide 1.0% (AZOPT) as Adjunctive Therapy to Travoprost 0.004% (TRAVATAN) in Patients With Chronic Angle-Closure Glaucoma [NCT00758342]	Phase 4	37 participants (Actual)	Interventional	2006-05-31	Terminated(stopped due to difficulty of enrolling patients)
Effects of Topical Hypotensive Drugs on Circadian Ocular Perfusion Pressure and Ocular Blood Flow in Patients With Open-Angle Glaucoma [NCT00800540]	Phase 4	35 participants (Actual)	Interventional	2009-02-28	Completed
[NCT00767494]	Phase 3	17 participants (Actual)	Interventional	2008-10-31	Terminated(stopped due to Project Cancelled)
[NCT00767481]	Phase 3	6 participants (Actual)	Interventional	2008-10-31	Terminated(stopped due to Project Cancelled)
A Comparison of Brinzolamide Ophthalmic Suspension, 1% (Azopt) TID vs. Placebo TID Added to Latanoprost Ophthalmic Solution, 0.005% (Xalatan) in Patients With Elevated IOP on a Prostaglandin [NCT00759941]	Phase 4	86 participants (Actual)	Interventional	2007-10-31	Completed
Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension [NCT01297517]	Phase 3	1,001 participants (Actual)	Interventional	2011-02-28	Completed
Comparison of Efficacy and Safety of Brinzolamide/Timolol Fixed Combination (AZARGA™) vs Brinzolamide (AZOPT®) and Timolol in Chinese Subjects With Open-Angle Glaucoma or Ocular Hypertension [NCT01357616]	Phase 3	328 participants (Actual)	Interventional	2010-11-30	Completed
IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00527501]	Phase 2	136 participants (Actual)	Interventional	2007-08-31	Completed
The Effects of the Water Drinking Test on Intraocular Pressure of Glaucoma Patients Undergoing 24 Hour Continuous Monitoring With the SENSIMED Triggerfish [NCT01507584]		23 participants (Actual)	Interventional	2011-08-31	Completed
[NCT00440141]	Phase 4	40 participants (Actual)	Interventional	2006-07-31	Completed
Efficacy and Safety of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT01309204]	Phase 3	1,184 participants (Actual)	Interventional	2011-05-31	Completed
Patient Preference Comparison of AZARGA Versus COSOPT After Single Doses in Patients With Open-Angled Glaucoma or Ocular Hypertension [NCT01471158]	Phase 4	120 participants (Actual)	Interventional	2010-09-30	Completed
A Multiple-Dose Study of the IOP-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% When Added to a PGA as Adjunctive Therapy Over a 24 Hour Period in Patients With Glaucoma or Ocular Hypertension [NCT00300079]	Phase 4	30 participants (Anticipated)	Interventional	2006-09-30	Completed
[NCT00314158]	Phase 3	523 participants (Actual)	Interventional	2005-11-30	Completed
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension [NCT00326092]	Phase 2	88 participants	Interventional	2006-05-31	Completed
Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide/Brimonidine Ophthalmic Suspension 1% to Simbrinza® in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes [NCT04944290]	Phase 3	447 participants (Actual)	Interventional	2021-05-28	Completed
Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension [NCT00061516]	Phase 3	78 participants (Actual)	Interventional	2003-01-31	Completed
Safety and Efficacy to Reduce the IOP of the Fixed Association of Latanoprost 0.005% (50 μg/mL)/ Brinzolamide 1% (10mg/mL) Drops, Compared to Latanoprost 0.005% (50 μg/mL) Drops, in Patients With Open Angle Glaucoma or Ocular Hypertension [NCT01721707]	Phase 3	0 participants (Actual)	Interventional	2012-12-31	Withdrawn(stopped due to withdrawn by industry)
Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma [NCT00869141]	Phase 4	52 participants (Actual)	Interventional	2009-03-31	Completed
Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT01340014]	Phase 4	112 participants (Actual)	Interventional	2011-09-30	Completed
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension [NCT00314171]	Phase 3	437 participants (Actual)	Interventional	2005-10-31	Completed
A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension [NCT00471380]	Phase 4	46 participants (Actual)	Interventional	2007-03-31	Completed
Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination As Adjunctive Therapy to Travoprost [NCT01937299]	Phase 4	307 participants (Actual)	Interventional	2013-10-31	Completed
Effect of Topical Prophylaxis With Brinzolamide-brimonidine Fixed Combination on Intraocular Pressure Elevation After Intravitreal Injections of Anti-vascular Endothelial Growth Factors [NCT04523844]		47 participants (Actual)	Interventional	2020-05-11	Completed
Study of the Efficacy of Brinzolamide 1% Plus Brimonidine 0.2% Versus Brimonidine 0.2% in the Prevention of Intraocular Pressure Rise After Nd-YAG Laser Capsulotomy [NCT03192826]	Phase 4	79 participants (Actual)	Interventional	2016-06-20	Completed
A 6-week, Double Masked, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Twice-daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to Travoprost 0.004% in Reducing Intraocular Pressure in Patients With No [NCT03150160]	Phase 4	1 participants (Actual)	Interventional	2017-09-21	Completed
A Descriptive Comfort Study of Brinzolamide 1% / Brimonidine Tartrate 0.2% Fixed Combination Ophthalmic Suspension, Brinzolamide 1% Ophthalmic Suspension and Brimonidine Tartrate 0.2% Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hype [NCT01426867]	Phase 2	103 participants (Actual)	Interventional	2011-09-30	Completed
Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension [NCT00372827]	Phase 4	245 participants	Interventional	2004-02-29	Completed
Assessing the Safety and Efficacy of Switching to AZARGA® (Brinzolamide/Timolol Fixed Combination) as Replacement Therapy in Patients With Uncontrolled Intraocular Pressure in Taiwan [NCT01484951]	Phase 4	74 participants (Actual)	Interventional	2011-05-31	Completed
A 6-Week Proof-of-Concept Study Evaluating the Safety and IOP-Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension [NCT02140060]	Phase 2	327 participants (Actual)	Interventional	2014-06-30	Completed
Clinical Evaluation of Patients With X-linked Retinoschisis (XLRS) [NCT02331173]		66 participants (Actual)	Observational	2012-11-30	Completed
Therapeutic Equivalence Study of Generic Brinzolamide 1% Ophthalmic Suspension Compared to Reference Listed Drug Azopt® (Brinzolamide) Ophthalmic Suspension 1% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension. [NCT05022004]	Phase 3	599 participants (Actual)	Interventional	2021-12-20	Completed
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Canada [NCT01415401]	Phase 4	57 participants (Actual)	Interventional	2011-09-30	Completed
Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as Adjunctive Therapy to a Prostaglandin Analogue [NCT01937312]	Phase 4	282 participants (Actual)	Interventional	2013-10-31	Completed
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Brazil [NCT01514734]	Phase 4	9 participants (Actual)	Interventional	2012-03-31	Terminated(stopped due to Low recruitment rate)
Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification [NCT03494257]		62 participants (Actual)	Interventional	2017-09-04	Completed
Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue [NCT02419508]	Phase 4	290 participants (Actual)	Interventional	2015-08-07	Completed
Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) [NCT02730871]	Phase 4	173 participants (Actual)	Interventional	2016-06-24	Terminated(stopped due to Enrollment Challenges)
Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination Therapy [NCT01978600]	Phase 4	89 participants (Actual)	Interventional	2013-10-31	Completed
The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension [NCT02325518]	Phase 4	218 participants (Actual)	Interventional	2014-12-31	Completed
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America [NCT01518244]	Phase 4	50 participants (Actual)	Interventional	2011-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00471380 (1) [back to overview]	Intra Ocular Pressure (IOP)
NCT00758342 (1) [back to overview]	Mean IOP (Intraocular Pressure)
NCT00759941 (4) [back to overview]	Mean Change From Baseline in Intraocular Pressure, 12 PM, at 3 Months
NCT00759941 (4) [back to overview]	Mean Change From Baseline in Intraocular Pressure, 4 PM, at 3 Months
NCT00759941 (4) [back to overview]	Mean Change From Baseline in Intraocular Pressure, 8 AM, at 3 Months
NCT00759941 (4) [back to overview]	Mean Change From Baseline in Intraocular Pressure, Diurnal, at 3 Months
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in End Diastolic Velocity in the Ophthalmic Artery at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Intraocular Pressure (IOP) at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Mean Flow Value in the Inverotemporal Peripapillary Retina at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Mean Flow Value in the Superotemporal Peripapillary Retina at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Peak Systolic Velocity in the Central Retinal Artery at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Peak Systolic Velocity in the Ophthalmic Artery at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Systolic Blood Pressure at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Vascular Resistance in the Central Retinal Artery at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Vascular Resistance in the Ophthalmic Artery at 6 Weeks
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Circadian Diastolic Ocular Perfusion Pressure at Week 6
NCT00800540 (12) [back to overview]	Mean Change From Baseline in Diastolic Blood Pressure at Week 6
NCT00869141 (3) [back to overview]	Intraocular Pressure Control After Ahmed Valve Implantation for Glaucoma
NCT00869141 (3) [back to overview]	Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma
NCT00869141 (3) [back to overview]	Intraocular Pressure of Eyes With Hypertensive Phase Versus Without Hypertensive Phase
NCT00961649 (2) [back to overview]	Mean Change in Intraocular Pressure (IOP) From Baseline to Each of the Assessment Time Points (8 AM, + 2 Hrs, + 7 Hrs, and + 9 Hrs) at Week 6 - Brinz/Brim, Brinz, Brim
NCT00961649 (2) [back to overview]	Mean Change in Intraocular Pressure (IOP) From Baseline to Each of the Assessment Time Points (8 AM, +2 Hrs, +7 Hrs, and +9 Hrs) at Week 6 - Brinz/Brim, Brinz+Brim
NCT01263444 (4) [back to overview]	Percentage of Patients Reaching the Target IOP (≤ 18 mmHg)
NCT01263444 (4) [back to overview]	Mean Change From Baseline in IOP Per Prostaglandin Group at Week 12
NCT01263444 (4) [back to overview]	Mean Change From Baseline in Intraocular Pressure (IOP) at Week 12
NCT01263444 (4) [back to overview]	Mean Change From Baseline in IOP at Week 4
NCT01297517 (1) [back to overview]	Mean IOP at Month 3 for Each Assessment Timepoint (8 AM, + 2 h, + 7 h, and + 9 h)
NCT01297920 (1) [back to overview]	Mean Intraocular Pressure (IOP) at Each Assessment Timepoint (8 AM, +2 h, +7 h, and +9 h) at Month 3
NCT01309204 (1) [back to overview]	Mean Diurnal IOP Change From Baseline at Month 3
NCT01310777 (1) [back to overview]	Mean Diurnal IOP Change From Baseline at Month 3
NCT01340014 (2) [back to overview]	Ocular Discomfort
NCT01340014 (2) [back to overview]	Preferred Treatment
NCT01357616 (4) [back to overview]	Mean Diurnal IOP Change From Baseline at Week 8
NCT01357616 (4) [back to overview]	Mean IOP Change From Baseline at 11 AM
NCT01357616 (4) [back to overview]	Mean IOP Change From Baseline (5 PM) at Week 8
NCT01357616 (4) [back to overview]	Mean IOP Change From Baseline at 9 AM
NCT01415401 (2) [back to overview]	Percentage of Subjects Who Reach Target IOP (≤ 18 mmHg)
NCT01415401 (2) [back to overview]	Change in IOP at the Final Visit From Prior Brimonidine 0.2%/Timolol 0.5% Fixed Combination (COMBIGAN®) Therapy (i.e. From Baseline)
NCT01426867 (1) [back to overview]	Mean Ocular Discomfort Score
NCT01484951 (2) [back to overview]	Change in Intraocular Pressure (IOP) at the Final Visit From Prior Beta-blocker Monotherapy (Timolol 0.5% Only)
NCT01484951 (2) [back to overview]	Percentage of Patients With Target IOP (≤18 mmHg), Regardless of Prior Therapy
NCT01514734 (1) [back to overview]	Change in Intraocular Pressure (IOP) at 8 Weeks From Baseline (Prior Therapy).
NCT01518244 (2) [back to overview]	Mean Change in Intraocular Pressure (IOP) From Baseline (Prior Therapy) at Week 8
NCT01518244 (2) [back to overview]	Percentage of Subjects Who Reach Target IOP (≤18 mmHg) at Week 8
NCT01722604 (2) [back to overview]	Change in Intraocular Pressure (IOP) From Baseline to Week 12
NCT01722604 (2) [back to overview]	Intraocular Pressure (IOP) at Week 12
NCT01937299 (3) [back to overview]	Mean Diurnal IOP Change From Baseline to Week 6
NCT01937299 (3) [back to overview]	Mean Diurnal Intraocular Pressure (IOP) at Week 6
NCT01937299 (3) [back to overview]	Mean Diurnal IOP Percentage Change From Baseline to Week 6
NCT01937312 (4) [back to overview]	Mean Diurnal Intraocular Pressure (IOP) at Week 6
NCT01937312 (4) [back to overview]	Mean Diurnal IOP Change From Baseline to Week 6
NCT01937312 (4) [back to overview]	Mean Diurnal IOP Percentage Change From Baseline to Week 6
NCT01937312 (4) [back to overview]	Mean IOP at Week 6 for Each Time Point (8 AM, 10 AM, 3 PM, 5 PM)
NCT01978600 (3) [back to overview]	Mean 24-hour IOP at Week 4
NCT01978600 (3) [back to overview]	Mean Diurnal IOP at Week 4
NCT01978600 (3) [back to overview]	Mean Nocturnal IOP at Week 4
NCT02140060 (1) [back to overview]	Mean IOP at Week 6
NCT02325518 (2) [back to overview]	Least Squares Mean Change From Baseline in Intraocular Pressure (IOP) at 11 AM
NCT02325518 (2) [back to overview]	Least Squares Mean Change From Baseline in IOP at 9 AM
NCT02339584 (1) [back to overview]	Mean Diurnal IOP Change From Baseline at Month 3
NCT02419508 (7) [back to overview]	Mean Diurnal IOP at Week 6
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline at 09:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Change From Baseline (on PGA) in Diurnal IOP (Mean of 09:00 and 11:00 Time Points) at Week 6
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline in IOP at 11:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Change From Baseline in IOP at 09:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Change From Baseline in IOP at 11:00 at Week 6
NCT02419508 (7) [back to overview]	Mean Percentage Change From Baseline in Diurnal IOP at Week 6
NCT02512042 (1) [back to overview]	Mean Difference in Intraocular Pressure (IOP) of Both Eyes Between the Two Treatment Groups at Four Time Points
NCT02730871 (5) [back to overview]	Mean Percentage Change From Baseline in Diurnal IOP at Week 6
NCT02730871 (5) [back to overview]	Mean Change From Baseline in IOP (09:00, 11:00) at Week 6
NCT02730871 (5) [back to overview]	Mean Change From Baseline in Diurnal Intraocular Pressure (IOP) (Mean of Changes at 09:00 and 11:00 Time Points) at Week 6
NCT02730871 (5) [back to overview]	Mean Percentage Change From Baseline in IOP (09:00, 11:00) at Week 6
NCT02730871 (5) [back to overview]	Mean Diurnal IOP at Week 6
NCT02770248 (4) [back to overview]	Least Squares Mean Change From Baseline in IOP for Each Time Point (8 AM Through 6 AM) at Week 4
NCT02770248 (4) [back to overview]	Least Squares Mean Change From Baseline in Nocturnal IOP at Week 4
NCT02770248 (4) [back to overview]	Least Squares Mean Change From Baseline in Daytime IOP at Week 4
NCT02770248 (4) [back to overview]	Least Squares Mean Change From Baseline in 24-hr Intraocular Pressure (IOP) at Week 4
NCT03192826 (4) [back to overview]	Intraocular Pressure (IOP) at 3 Hours After Nd-YAG Posterior Capsulotomy
NCT03192826 (4) [back to overview]	Intraocular Pressure (IOP) at 24 Hourw After Nd-YAG Posterior Capsulotomy
NCT03192826 (4) [back to overview]	Intraocular Pressure (IOP) at 1 Week After Nd-YAG Posterior Capsulotomy
NCT03192826 (4) [back to overview]	Intraocular Pressure (IOP) at 1 Hour After Nd-YAG Posterior Capsulotomy
NCT03896633 (2) [back to overview]	Change in Intraocular Pressure (IOP)
NCT03896633 (2) [back to overview]	Intraocular Pressure (IOP)
NCT04024072 (1) [back to overview]	Mean Change in Intra-ocular Pressure

Intra Ocular Pressure (IOP)

Intra Ocular Pressure, calculated as AUC (area under the curve) of IOP measured from 8.00 a.m. to 8.00 p.m, at different time-points (NCT00471380)
Timeframe: Baseline, end of each period (week 8, week 16, week 24)

Intervention	mm Hg (millimeters mercury)*week (Mean)
	Week 8	Week 16	Week 24
Crossover Group ABB	179.20	188.82	201.50
Crossover Group BAA	191.89	196.26	191.93

Intervention	mm Hg (millimeters mercury) (Mean)
	9 AM measurement	4 PM measurement
Travoprost 0.004% + Brinzolamide 1.0%	17.58	17.11
Travoprost 0.004% + Tears Natural	20.59	18.50

Intervention	cm/s (centimeters per second) (Mean)
	9:00 am	1:00 pm	5:00 pm	9:00 pm	12:00 am	3:00 am	6:00 am
AZARGA	-0.0	-0.6	0.5	0.4	-0.8	-0.1	-0.2
COMBIGAN	-0.8	-1.2	0.2	-0.8	-1.4	-0.6	-0.5

Intervention	mmHg in 1 year postop (Mean)
Hypertensive Phase Group	15.1
Non-hypertensive Phase Group	11.4

Intervention	millimeters mercury (mmHg) (Least Squares Mean)
	Change from Baseline (BL) at 8 AM	Change from BL at +2 hours relative to 8 AM dosing	Change from BL at +7 hours relative to 8 AM dosing	Change from BL at +9 hours relative to 8 AM dosing
Brim	-4.1	-5.3	-3.0	-5.9
Brinz	-5.7	-4.7	-2.8	-3.9
Brinz/Brim	-5.5	-8.5	-5.4	-6.8

Intervention	mmHg (Mean)
	AZARGA + Latanoprost (n=22)	AZARGA + Travoprost (n=15)
Azarga	-7.1	-5.1

Intervention	millimeters mercury (mm Hg) (Least Squares Mean)
	8 am (before study drug instillation)	+2 hrs relative to 8 am dosing	+7 hrs relative to 8 am dosing	+9 hrs relative to 8 am dosing
Brimonidine	23.3	19.7	21.3	18.8
Brinzolamide	21.6	20.4	20.4	20.0
Brinzolamide/Brimonidine	20.5	17.2	18.7	17.0

Intervention	millimeters mercury (mm HG) (Least Squares Mean)
	8 AM (before study drug instillation)	+ 2 hours relative to 8 AM dosing	+ 7 hours relative to 8 AM dosing	+ 9 hours relative to 8 AM dosing
Brimonidine	23.2	19.9	21.5	18.9
Brinz/Brim	21.1	18.0	19.5	17.2
Brinzolamide	22.0	20.8	20.7	20.4

Intervention	mmHg (Least Squares Mean)
	Change from baseline at Week 2	Change from baseline at Week 4	Change from baseline at Week 8
AZARGA	-7.5	-7.6	-7.4
AZOPT + Timolol	-6.8	-6.8	-6.5

Intervention	mmHg (Mean)
Brinzolamide 1% Ophthalmic Suspension	-5.3
Azopt 1% Ophthalmic Suspension	-5.4

Intervention	mmHg (Mean)
Brinzolamide 1% Ophthalmic Suspension	20.6
Azopt 1% Ophthalmic Suspension	20.8

Intervention	Arbitrary Units (Mean)
	9:00 am	1:00 pm	5:00 pm	9:00 pm
AZARGA	15.9	-40.7	-38.7	182.3
COMBIGAN	-70.0	-89.2	-69.1	-91.0

Intervention	Arbitrary Units (Mean)
	9:00 am	1:00 pm	5:00 pm	9:00 pm
AZARGA	-272.4	-12.1	-26.7	14.0
COMBIGAN	-43.5	248.9	-51.3	-33.2

Intervention	mmHg (Mean)
	8 AM	10 AM	3 PM	5 PM
SIMBRINZA	19.4	15.8	17.2	15.6
Vehicle	21.4	20.2	19.9	19.9

Intervention	mmHg (Mean)
	8 AM	10 AM	12 PM	4PM	8 PM, n=44, 44, 44, 43, 45, 43
AZOPT	22.0	19.7	19.5	19.1	19.3
TRAV Z	19.3	17.4	17.2	17.6	17.3
TRAV Z + AZOPT	20.3	18.2	18.0	18.0	18.1
TravA/Brinz	20.2	18.9	18.9	18.5	18.4
TravB/Brinz	18.7	17.2	17.3	17.5	17.5
TravC/Brinz	19.9	18.2	17.7	17.3	17.2

Intervention	mmHg (Least Squares Mean)
	Baseline	Mean change pooled over Week 4 and Week 8
BRI/TIM	17.0	-3.3
DOR/TIM	17.0	-3.4

Intervention	mmHg (Least Squares Mean)
	Baseline	Change at Pool (Week 4, Week 8)
BRI/TIM	17.4	-3.3
DOR/TIM	17.3	-2.9

Intervention	mmHg (Mean)
	Baseline	Change from baseline
SIMBRINZA + PGA	23.4	-4.9
Vehicle + PGA	23.4	-2.5

Intervention	mmHg (Mean)
	8AM Visit Day 14	8AM Visit Day 42	10AM Visit Day 14	10AM Visit Day 42
Azopt® (Brinzolomide Ophthalmic Suspension USP 1%)	19.75	18.66	19.18	18.16
Generic Brinzolamide Ophthalmic Suspension USP 1%	19.35	18.53	18.70	17.94

Intervention	mmHg (Mean)
	Baseline 9:00 Hr	Baseline 11:00 Hr	Change from Baseline 9:00 Hr	Change from Baseline 11:00 Hr
Simbrinza + Duotrav	22.2	21.4	-4.4	-5.4
Vehicle + Duotrav	22.5	21.4	-3.2	-2.5

Intervention	percentage change (Mean)
	Percent change at 9:00 Hr	Percent change at 11:00 Hr
Simbrinza + Duotrav	-20.2	-25.0
Vehicle + Duotrav	-14.1	-11.7

Intervention	mmHg (Least Squares Mean)
	8AM	10AM	12PM	2PM	4PM	6PM	8PM	10PM	12AM	2AM	4AM	6AM
SIMBRINZA	-3.28	-5.05	-4.03	-3.36	-3.95	-4.46	-3.42	-2.10	-1.79	-2.30	-1.42	-1.95
Vehicle	-0.49	-0.61	-0.27	-0.66	-0.51	-0.32	-0.72	-0.67	-0.83	-0.55	-0.98	-0.63

Intervention	mmHg (Mean)
	Baseline	3 hours
Artificial Tears	15.2	19.5
Brimonidine 0.2%	15.7	14.7
Brinzolamide/Brimonidine FC	15.6	12.7

brinzolamide

Description

Cross-References

Synonyms (112)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (2)

Protein Targets (54)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (61)

Molecular Functions (31)

Ceullar Components (36)

Bioassays (435)

Research

Studies (332)

Market Indicators

Research Demand Index: 76.95

Study Types

Clinical Trials (60)

Trial Overview

Trial Outcomes

Intra Ocular Pressure (IOP)

Mean IOP (Intraocular Pressure)

Mean Change From Baseline in Intraocular Pressure, 12 PM, at 3 Months

Mean Change From Baseline in Intraocular Pressure, 4 PM, at 3 Months

Mean Change From Baseline in Intraocular Pressure, 8 AM, at 3 Months

Mean Change From Baseline in Intraocular Pressure, Diurnal, at 3 Months

Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6

Mean Change From Baseline in End Diastolic Velocity in the Ophthalmic Artery at Week 6

Mean Change From Baseline in Intraocular Pressure (IOP) at Week 6

Mean Change From Baseline in Mean Flow Value in the Inverotemporal Peripapillary Retina at Week 6

Mean Change From Baseline in Mean Flow Value in the Superotemporal Peripapillary Retina at Week 6

Mean Change From Baseline in Peak Systolic Velocity in the Central Retinal Artery at Week 6

Mean Change From Baseline in Peak Systolic Velocity in the Ophthalmic Artery at Week 6

Mean Change From Baseline in Systolic Blood Pressure at Week 6

Mean Change From Baseline in Vascular Resistance in the Central Retinal Artery at Week 6

Mean Change From Baseline in Vascular Resistance in the Ophthalmic Artery at 6 Weeks

Mean Change From Baseline in Circadian Diastolic Ocular Perfusion Pressure at Week 6

Mean Change From Baseline in Diastolic Blood Pressure at Week 6

Intraocular Pressure Control After Ahmed Valve Implantation for Glaucoma

Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma

Intraocular Pressure of Eyes With Hypertensive Phase Versus Without Hypertensive Phase

Mean Change in Intraocular Pressure (IOP) From Baseline to Each of the Assessment Time Points (8 AM, + 2 Hrs, + 7 Hrs, and + 9 Hrs) at Week 6 - Brinz/Brim, Brinz, Brim

Mean Change in Intraocular Pressure (IOP) From Baseline to Each of the Assessment Time Points (8 AM, +2 Hrs, +7 Hrs, and +9 Hrs) at Week 6 - Brinz/Brim, Brinz+Brim

Percentage of Patients Reaching the Target IOP (≤ 18 mmHg)

Mean Change From Baseline in IOP Per Prostaglandin Group at Week 12

Mean Change From Baseline in Intraocular Pressure (IOP) at Week 12

Mean Change From Baseline in IOP at Week 4

Mean IOP at Month 3 for Each Assessment Timepoint (8 AM, + 2 h, + 7 h, and + 9 h)

Mean Intraocular Pressure (IOP) at Each Assessment Timepoint (8 AM, +2 h, +7 h, and +9 h) at Month 3

Mean Diurnal IOP Change From Baseline at Month 3

Mean Diurnal IOP Change From Baseline at Month 3

Ocular Discomfort

Preferred Treatment

Mean Diurnal IOP Change From Baseline at Week 8

Mean IOP Change From Baseline at 11 AM

Mean IOP Change From Baseline (5 PM) at Week 8

Mean IOP Change From Baseline at 9 AM

Percentage of Subjects Who Reach Target IOP (≤ 18 mmHg)

Change in IOP at the Final Visit From Prior Brimonidine 0.2%/Timolol 0.5% Fixed Combination (COMBIGAN®) Therapy (i.e. From Baseline)

Mean Ocular Discomfort Score

Change in Intraocular Pressure (IOP) at the Final Visit From Prior Beta-blocker Monotherapy (Timolol 0.5% Only)

Percentage of Patients With Target IOP (≤18 mmHg), Regardless of Prior Therapy

Change in Intraocular Pressure (IOP) at 8 Weeks From Baseline (Prior Therapy).

Mean Change in Intraocular Pressure (IOP) From Baseline (Prior Therapy) at Week 8

Percentage of Subjects Who Reach Target IOP (≤18 mmHg) at Week 8

Change in Intraocular Pressure (IOP) From Baseline to Week 12

Intraocular Pressure (IOP) at Week 12

Intervention	mmHg (Mean)
	Baseline	24 hours
Artificial Tears	15.2	15.8
Brimonidine 0.2%	15.7	15.5
Brinzolamide/Brimonidine FC	15.6	14.6

Intervention	mmHg (Mean)
	Baseline	1 week
Artificial Tears	15.2	15.6
Brimonidine 0.2%	15.7	15.3
Brinzolamide/Brimonidine FC	15.6	15.5

Intervention	mmHg (Mean)
	Baseline	1 hour
Artificial Tears	15.2	19.5
Brimonidine 0.2%	15.7	14.7
Brinzolamide/Brimonidine FC	15.6	13.7

Intervention	mmHg (Mean)
Brinzolamide 1% Ophthalmic Suspension	-4.85
Azopt 1% Ophthalmic Suspension	-4.70

Intervention	mmHg (Mean)
Brinzolamide 1% Ophthalmic Suspension	20.07
Azopt 1% Ophthalmic Suspension	19.89

Intervention	mmHG (Mean)
	8AM Day 14	10AM Day 14	8AM Day 42	10AM Day 42
Perrigo Active	-4.25	-4.22	-4.43	-4.05
Reference Active	-3.80	-4.00	-4.20	-4.06